<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544217</url>
  </required_header>
  <id_info>
    <org_study_id>KH176-101</org_study_id>
    <nct_id>NCT02544217</nct_id>
  </id_info>
  <brief_title>A Dose-escalating Clinical Trial With KH176</brief_title>
  <official_title>A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khondrion BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Drug Research Unit Ghent, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Khondrion BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mitochondrial Diseases are rare progressive, multi-system, often early fatal disorders&#xD;
      affecting both children and adults. KH176 is a novel chemical entity currently under&#xD;
      development for the treatment of inherited mitochondrial diseases, including MELAS&#xD;
      (Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes), Leigh's Disease&#xD;
      and Leber's Hereditary Optic Neuropathy (LHON). KH176 is a potent intracellular redox&#xD;
      modulating agent targeting the reactive oxygen species which are important in the&#xD;
      pathogenesis of disorders of mitochondrial oxidative phosphorylation. After demonstrating a&#xD;
      favourable safety profile in the pre-clinical testing, the safety, tolerability and&#xD;
      pharmacokinetic and pharmacodynamic characteristics of the compound will now be evaluated in&#xD;
      healthy male subjects in this trial&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF)</measure>
    <time_frame>Baseline, 1, 2, 4, 6, 8, 12, 24 hours, 7 day follow up</time_frame>
    <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics of KH176</measure>
    <time_frame>Day 1, day 7</time_frame>
    <description>Change from baseline in biochemistry related to Oxidative Phosphorylation (OXPHOS) (glutathione, lactate); MAD group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship to Study Drug and Severity of Treatment-emergent Adverse Events</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate (SAD Group)</measure>
    <time_frame>Baseline (pre-dose Day1), 24h post dose, FU (7 days after last dosing)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days after last dosing)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24 h postdose, FU (7 days after last dosing)</time_frame>
    <description>Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin. SAD</measure>
    <time_frame>Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin Concentration - SAD</measure>
    <time_frame>Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)</time_frame>
    <description>Erythrocyte mean corpuscular hemoglobin concentration (MCHC) is a measure of the average concentration of hemoglobin per red blood cell. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume - SAD</measure>
    <time_frame>Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Change From Baseline in ECG Results by Time Point: QTcF</measure>
    <time_frame>Baseline, Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7</time_frame>
    <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple-dose part.&#xD;
QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h, FU (7 days post-dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post-dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value ateach timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post-dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hemoglobin. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. MAD</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated time points for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each time point are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin Concentration. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Aspartate Aminotransferase. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Protein. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Gamma-GT. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alkaline Phosphatase. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Chloride. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Bilirubin. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alanine Aminotransferase. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine Kinase. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Urea. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Sodium. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Potassium. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Phosphate. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Calcium (Corrected for Albumin). SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Uric Acid. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triiodothyronine (T3). SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lipase. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: (Fasting) Glucose. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Human Serum Albumin. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Cholesterol. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: High Density Lipoproteins. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triglycerides. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Low Density Lipoproteins. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Bicarbonate. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroid-stimulating Hormone. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroxine (T4). SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lactate. SAD Group</measure>
    <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Protein. MAD Group</measure>
    <time_frame>Baseline (pre-dose Day1), Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alkaline Phosphatase. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Aspartate Aminotransferase. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatine Kinase. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Gamma GT. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Bilirubin. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Urea. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatinine. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Sodium. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Potassium. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Chloride. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Calcium (Corrected for Albumin). MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Uric Acid. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lipase. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alanine Aminotransferase. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Phosphate. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Human Serum Albumin. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Fasting Glucose. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Cholesterol. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Triglycerides. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Low Density Lipoproteins. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: High Density Lipoproteins. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroid-stimulating Hormone. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Trilodothyronine (T3). MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroxine (T4). MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Bicarbonate. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lactate. MAD Group</measure>
    <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
    <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phospholipidosis</measure>
    <time_frame>Day 1, Day 7</time_frame>
    <description>Change from Day 1 to Day 7 in di-docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate (di-22:6-BMP) and normalized di-22:6-BMP (urine) - MAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Change From Baseline in ECG Results by Time Point: Corrected QT Interval According to Barret's Formaula (QTcB)</measure>
    <time_frame>Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up</time_frame>
    <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Change From Baseline in ECG Results by Time Point: P Wave-Q Wave Interval (PQ Interval)</measure>
    <time_frame>Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up</time_frame>
    <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the PQ interval the average of the 3 recordings will be taken as baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Change From Baseline in ECG Results by Time Point: the Interval That Denotes Depolarization of the Ventricles, Between the Beginning of the Q Wave and the End of the S Wave (QRS Interval)</measure>
    <time_frame>Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up</time_frame>
    <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Change From Baseline in ECG Results by Time Point: QT Interval</measure>
    <time_frame>Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up</time_frame>
    <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: Change From Baseline in ECG Results by Time Point: PQ Interval</measure>
    <time_frame>Pre-dose, Day 1, Day 7</time_frame>
    <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: Change From Baseline in ECG Results by Time Point: QRS Interval</measure>
    <time_frame>Pre-dose, Day 1, Day 7</time_frame>
    <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: Change From Baseline in ECG Results by Time Point: QT Interval</measure>
    <time_frame>Pre-dose, Day 1, Day 7</time_frame>
    <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: Change From Baseline in ECG Results by Time Point: QTcB Interval</measure>
    <time_frame>Pre-dose, Day1, Day 7</time_frame>
    <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) of KH176 Over 24 Hours: SAD</measure>
    <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
    <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) of KH183: SAD</measure>
    <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
    <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of KH176: SAD Group</measure>
    <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
    <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of KH183 Over 24 Hours: SAD</measure>
    <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
    <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of KH183 (Active Metabolite of KH176): MAD Group</measure>
    <time_frame>Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Cmax was obtained directly from the concentration-time data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of KH176: MAD</measure>
    <time_frame>pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of KH176 Over 24 Hours: SAD</measure>
    <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
    <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Peak Plasma Concentration (Tmax) of KH183: SAD</measure>
    <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
    <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of KH176 at Day 1, Day 7: MAD Group</measure>
    <time_frame>pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of KH183 (Active Metabolite of KH176): MAD Group</measure>
    <time_frame>Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. tmax was obtained directly from the concentration-time data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Factor (Racc) of KH176 Over 7 Days: MAD Group</measure>
    <time_frame>Pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. Racc was calculated as follows: AUCtau day 7/ AUCtau day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Factor (Racc) of KH183 (Active Metabolite of KH176): MAD Group</measure>
    <time_frame>Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Accumulation factor was calculated as follows: AUCtau day 7/ AUCtau day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH183: SAD Group</measure>
    <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
    <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH176: SAD Group</measure>
    <time_frame>pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
    <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUCtau) of KH176: MAD Group:</measure>
    <time_frame>Pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve During a Dose Interval (AUCtau) of KH183 (Active Metabolite of KH176): MAD Group</measure>
    <time_frame>Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH183: SAD</measure>
    <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
    <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH176: SAD</measure>
    <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
    <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KH176: Percentage of Administered Dose Excreted in Urine: SAD</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KH183: Percentage of Administered Dose Excreted in Urine: SAD</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KH176 + KH183: Percentage of Administered Dose Excreted in Urine: SAD</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KH176: Percentage of Administered Dose Excreted in Urine: MAD</measure>
    <time_frame>Day 7 post dose</time_frame>
    <description>Urine concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KH183: Percentage of Administered Dose Excreted in Urine: MAD</measure>
    <time_frame>Post dose Day 7</time_frame>
    <description>Urine concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KH173 + KH183: Percentage of Administered Dose Excreted in Urine: MAD</measure>
    <time_frame>Day 7 Post dose</time_frame>
    <description>Urine concentrations of KH176 and KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>MELAS</condition>
  <condition>LHON</condition>
  <condition>Leigh Syndrome</condition>
  <condition>Mitochondrial Disease</condition>
  <condition>Mitochondrial DNA tRNALeu(UUR) m.3243A&lt;G Mutation</condition>
  <arm_group>
    <arm_group_label>Single Escalating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 alternating groups receiving escalating single doses of active/placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Escalating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 multiple escalating groups, receiving active/placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KH176</intervention_name>
    <arm_group_label>Multiple Escalating</arm_group_label>
    <arm_group_label>Single Escalating</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Multiple Escalating</arm_group_label>
    <arm_group_label>Single Escalating</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as assessed by medical history, physical examination, Vital Signs, Clinical&#xD;
             Laboratory, ECG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergies,&#xD;
&#xD;
          -  Concomitant medication,&#xD;
&#xD;
          -  concomitant disease,&#xD;
&#xD;
          -  relevant surgery,&#xD;
&#xD;
          -  recent blood donation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Drug Research Unit Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>April 19, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <results_first_submitted>June 23, 2020</results_first_submitted>
  <results_first_submitted_qc>October 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2020</results_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leigh Disease</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All studies were conducted at the Drug Research Unit Ghent. Participants agreed to stay in the Drug Research Unit during the first 24 h after dosing (SAD) and during Day 8 (MAD).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Ascending Group I</title>
          <description>2 alternating groups receiving escalating single doses of active/placebo&#xD;
KH176&#xD;
placebo</description>
        </group>
        <group group_id="P2">
          <title>Single Ascending Group II</title>
          <description>2 alternating groups receiving escalating single doses of active/placebo&#xD;
KH176&#xD;
placebo</description>
        </group>
        <group group_id="P3">
          <title>Multiple Ascending Group III</title>
          <description>3 multiple escalating groups, receiving active/placebo&#xD;
KH176&#xD;
placebo</description>
        </group>
        <group group_id="P4">
          <title>Multiple Ascending Group IV</title>
          <description>3 multiple escalating groups, receiving active/placebo&#xD;
KH176&#xD;
placebo</description>
        </group>
        <group group_id="P5">
          <title>Multiple Ascending Group V</title>
          <description>3 multiple escalating groups, receiving active/placebo&#xD;
KH176&#xD;
placebo</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Group receiving placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6">Two subjects prematurely withdrew from the study for non-medical reasons and were replaced.</participants>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>SAD:14 subjects divided in two groups of 7 subjects were included. Two subjects prematurely withdrew from the study after dosing period 2 for non-medical reasons. MAD part:18 subjects divided in 3 groups of 6 subjects were included. Two subjects prematurely withdrew from the study for non-medical reasons and were replaced.</population>
      <group_list>
        <group group_id="B1">
          <title>SAD Group I</title>
          <description>SAD group I: 10mg, 100mg, 800mg</description>
        </group>
        <group group_id="B2">
          <title>SAD Group II</title>
          <description>SAD group II: 30mg, 300mg, 2000mg</description>
        </group>
        <group group_id="B3">
          <title>MAD Group III</title>
          <description>MAD group III:100mg bis in die (BID)</description>
        </group>
        <group group_id="B4">
          <title>MAD Group IV</title>
          <description>MAD group IV: 200mg BID</description>
        </group>
        <group group_id="B5">
          <title>MAD Group V</title>
          <description>MAD group V: 400mg BID</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Placebo group</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.4" spread="10.5"/>
                    <measurement group_id="B2" value="32.0" spread="11.3"/>
                    <measurement group_id="B3" value="40.8" spread="13.0"/>
                    <measurement group_id="B4" value="34.5" spread="11.6"/>
                    <measurement group_id="B5" value="44.0" spread="8.2"/>
                    <measurement group_id="B6" value="44.7" spread="9.8"/>
                    <measurement group_id="B7" value="40.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178.07" spread="6.56"/>
                    <measurement group_id="B2" value="176.01" spread="8.11"/>
                    <measurement group_id="B3" value="184.63" spread="2.81"/>
                    <measurement group_id="B4" value="181.75" spread="5.25"/>
                    <measurement group_id="B5" value="175.70" spread="3.18"/>
                    <measurement group_id="B6" value="175.55" spread="8.25"/>
                    <measurement group_id="B7" value="184.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.86" spread="10.56"/>
                    <measurement group_id="B2" value="74.29" spread="12.61"/>
                    <measurement group_id="B3" value="89.05" spread="11.84"/>
                    <measurement group_id="B4" value="77.85" spread="11.96"/>
                    <measurement group_id="B5" value="81.10" spread="4.82"/>
                    <measurement group_id="B6" value="72.03" spread="6.06"/>
                    <measurement group_id="B7" value="80.0" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.09" spread="2.51"/>
                    <measurement group_id="B2" value="24.01" spread="4.01"/>
                    <measurement group_id="B3" value="26.10" spread="2.74"/>
                    <measurement group_id="B4" value="23.60" spread="3.82"/>
                    <measurement group_id="B5" value="26.28" spread="1.67"/>
                    <measurement group_id="B6" value="23.43" spread="1.98"/>
                    <measurement group_id="B7" value="24.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF)</title>
        <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.</description>
        <time_frame>Baseline, 1, 2, 4, 6, 8, 12, 24 hours, 7 day follow up</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>SAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF)</title>
          <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386.2" spread="17.2"/>
                    <measurement group_id="O2" value="395.0" spread="9.8"/>
                    <measurement group_id="O3" value="385.8" spread="14.8"/>
                    <measurement group_id="O4" value="399.3" spread="8.3"/>
                    <measurement group_id="O5" value="390.3" spread="14.6"/>
                    <measurement group_id="O6" value="393.5" spread="14.2"/>
                    <measurement group_id="O7" value="386.5" spread="10.9"/>
                    <measurement group_id="O8" value="385.3" spread="16.8"/>
                    <measurement group_id="O9" value="369.0" spread="14.1"/>
                    <measurement group_id="O10" value="386.5" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline (BL)at 1h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.8"/>
                    <measurement group_id="O2" value="-2.0" spread="8.7"/>
                    <measurement group_id="O3" value="-0.3" spread="3.8"/>
                    <measurement group_id="O4" value="-3.5" spread="6.0"/>
                    <measurement group_id="O5" value="0.8" spread="4.0"/>
                    <measurement group_id="O6" value="0.8" spread="5.7"/>
                    <measurement group_id="O7" value="0.3" spread="7.6"/>
                    <measurement group_id="O8" value="28.8" spread="19.0"/>
                    <measurement group_id="O9" value="4.5" spread="19.1"/>
                    <measurement group_id="O10" value="5.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 2h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="7.9"/>
                    <measurement group_id="O2" value="-4.0" spread="6.6"/>
                    <measurement group_id="O3" value="-1.8" spread="7.9"/>
                    <measurement group_id="O4" value="-4.8" spread="6.1"/>
                    <measurement group_id="O5" value="-4.8" spread="3.0"/>
                    <measurement group_id="O6" value="1.5" spread="6.0"/>
                    <measurement group_id="O7" value="7.8" spread="10.0"/>
                    <measurement group_id="O8" value="28.5" spread="14.1"/>
                    <measurement group_id="O9" value="2.5" spread="13.4"/>
                    <measurement group_id="O10" value="1.8" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 4h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="9.4"/>
                    <measurement group_id="O2" value="-2.2" spread="11.4"/>
                    <measurement group_id="O3" value="-3.8" spread="3.3"/>
                    <measurement group_id="O4" value="-4.3" spread="6.2"/>
                    <measurement group_id="O5" value="1.0" spread="5.7"/>
                    <measurement group_id="O6" value="3.8" spread="12.3"/>
                    <measurement group_id="O7" value="3.3" spread="7.2"/>
                    <measurement group_id="O8" value="26.0" spread="8.7"/>
                    <measurement group_id="O9" value="8.5" spread="17.7"/>
                    <measurement group_id="O10" value="0.3" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 6h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="3.6"/>
                    <measurement group_id="O2" value="-2.7" spread="6.0"/>
                    <measurement group_id="O3" value="4.3" spread="6.3"/>
                    <measurement group_id="O4" value="-4.0" spread="7.3"/>
                    <measurement group_id="O5" value="-1.0" spread="8.3"/>
                    <measurement group_id="O6" value="5.8" spread="8.1"/>
                    <measurement group_id="O7" value="5.5" spread="2.5"/>
                    <measurement group_id="O8" value="26.0" spread="7.9"/>
                    <measurement group_id="O9" value="8.5" spread="12.0"/>
                    <measurement group_id="O10" value="6.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 8h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="7.3"/>
                    <measurement group_id="O2" value="-7.2" spread="4.0"/>
                    <measurement group_id="O3" value="-5.5" spread="7.4"/>
                    <measurement group_id="O4" value="-1.8" spread="9.2"/>
                    <measurement group_id="O5" value="4.3" spread="10.3"/>
                    <measurement group_id="O6" value="-1.8" spread="9.0"/>
                    <measurement group_id="O7" value="0.8" spread="7.5"/>
                    <measurement group_id="O8" value="23.3" spread="12.3"/>
                    <measurement group_id="O9" value="-2.5" spread="13.4"/>
                    <measurement group_id="O10" value="0.5" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 12h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="6.7"/>
                    <measurement group_id="O2" value="-5.2" spread="4.8"/>
                    <measurement group_id="O3" value="-1.8" spread="2.6"/>
                    <measurement group_id="O4" value="-7.3" spread="6.8"/>
                    <measurement group_id="O5" value="0.0" spread="4.7"/>
                    <measurement group_id="O6" value="0.0" spread="8.0"/>
                    <measurement group_id="O7" value="8.0" spread="0.8"/>
                    <measurement group_id="O8" value="19.3" spread="11.1"/>
                    <measurement group_id="O9" value="5.5" spread="7.8"/>
                    <measurement group_id="O10" value="3.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="12.4"/>
                    <measurement group_id="O2" value="-7.5" spread="9.3"/>
                    <measurement group_id="O3" value="-4.0" spread="7.3"/>
                    <measurement group_id="O4" value="-4.8" spread="5.6"/>
                    <measurement group_id="O5" value="0.3" spread="6.2"/>
                    <measurement group_id="O6" value="-4.3" spread="6.5"/>
                    <measurement group_id="O7" value="0.3" spread="9.7"/>
                    <measurement group_id="O8" value="11.3" spread="4.7"/>
                    <measurement group_id="O9" value="-1.0" spread="8.5"/>
                    <measurement group_id="O10" value="-3.8" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="12.4"/>
                    <measurement group_id="O2" value="2.8" spread="7.9"/>
                    <measurement group_id="O3" value="-1.3" spread="10.8"/>
                    <measurement group_id="O4" value="2.8" spread="8.0"/>
                    <measurement group_id="O5" value="2.8" spread="13.1"/>
                    <measurement group_id="O6" value="5.0" spread="6.1"/>
                    <measurement group_id="O7" value="-5.0" spread="3.2"/>
                    <measurement group_id="O8" value="3.3" spread="7.6"/>
                    <measurement group_id="O9" value="5.5" spread="10.6"/>
                    <measurement group_id="O10" value="6.5" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamics of KH176</title>
        <description>Change from baseline in biochemistry related to Oxidative Phosphorylation (OXPHOS) (glutathione, lactate); MAD group</description>
        <time_frame>Day 1, day 7</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Mad group: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics of KH176</title>
          <description>Change from baseline in biochemistry related to Oxidative Phosphorylation (OXPHOS) (glutathione, lactate); MAD group</description>
          <population>Per protocol set</population>
          <units>ratio GSH/GSSG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ox glutathione (GSH)/Red Glutathati(GSSG) Day 1-0h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="872" spread="532"/>
                    <measurement group_id="O2" value="2083" spread="674"/>
                    <measurement group_id="O3" value="2275" spread="792"/>
                    <measurement group_id="O4" value="1584" spread="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSH/GSSG Day 7-0h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="919" spread="196"/>
                    <measurement group_id="O2" value="1923" spread="433"/>
                    <measurement group_id="O3" value="1918" spread="1007"/>
                    <measurement group_id="O4" value="1694" spread="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSH/GSSG Day 7-3h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="779" spread="87"/>
                    <measurement group_id="O2" value="2045" spread="338"/>
                    <measurement group_id="O3" value="1935" spread="699"/>
                    <measurement group_id="O4" value="1712" spread="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSH/GSSG Day 7-6h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1040" spread="335"/>
                    <measurement group_id="O2" value="2113" spread="687"/>
                    <measurement group_id="O3" value="1993" spread="863"/>
                    <measurement group_id="O4" value="1718" spread="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSH/GSSG Day 7-12h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1361" spread="606"/>
                    <measurement group_id="O2" value="1893" spread="279"/>
                    <measurement group_id="O3" value="1875" spread="697"/>
                    <measurement group_id="O4" value="1680" spread="657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relationship to Study Drug and Severity of Treatment-emergent Adverse Events</title>
        <time_frame>4 months</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O11">
            <title>MAD Group III 200mg</title>
            <description>100mg BID/Day (over 7 days)</description>
          </group>
          <group group_id="O12">
            <title>MAD Group IV 400mg</title>
            <description>200mg BID/Day (over 7 days)</description>
          </group>
          <group group_id="O13">
            <title>MAD Group V 800mg</title>
            <description>400mg BID/Day (over 7 days)</description>
          </group>
          <group group_id="O14">
            <title>Placebo</title>
            <description>MAD group: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship to Study Drug and Severity of Treatment-emergent Adverse Events</title>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>TEAE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="9"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="14"/>
                    <measurement group_id="O14" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlikely related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="9"/>
                    <measurement group_id="O14" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells 10^6/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.947" spread="0.488"/>
                    <measurement group_id="O2" value="4.933" spread="0.307"/>
                    <measurement group_id="O3" value="4.793" spread="0.455"/>
                    <measurement group_id="O4" value="5.030" spread="0.458"/>
                    <measurement group_id="O5" value="4.953" spread="0.247"/>
                    <measurement group_id="O6" value="5.137" spread="0.393"/>
                    <measurement group_id="O7" value="4.973" spread="0.141"/>
                    <measurement group_id="O8" value="4.623" spread="0.395"/>
                    <measurement group_id="O9" value="5.095" spread="0.120"/>
                    <measurement group_id="O10" value="4.985" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.200" spread="0.495"/>
                    <measurement group_id="O2" value="0.095" spread="0.260"/>
                    <measurement group_id="O3" value="0.063" spread="0.085"/>
                    <measurement group_id="O4" value="0.188" spread="0.153"/>
                    <measurement group_id="O5" value="0.170" spread="0.250"/>
                    <measurement group_id="O6" value="0.065" spread="0.197"/>
                    <measurement group_id="O7" value="0.173" spread="0.200"/>
                    <measurement group_id="O8" value="0.325" spread="0.185"/>
                    <measurement group_id="O9" value="0.185" spread="0.064"/>
                    <measurement group_id="O10" value="0.115" spread="0.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.215"/>
                    <measurement group_id="O2" value="-0.013" spread="0.149"/>
                    <measurement group_id="O3" value="0.185" spread="0.104"/>
                    <measurement group_id="O4" value="-0.052" spread="0.183"/>
                    <measurement group_id="O5" value="0.083" spread="0.127"/>
                    <measurement group_id="O6" value="-0.147" spread="0.041"/>
                    <measurement group_id="O7" value="-0.053" spread="0.209"/>
                    <measurement group_id="O8" value="0.125" spread="0.182"/>
                    <measurement group_id="O9" value="-0.150" spread="0.339"/>
                    <measurement group_id="O10" value="0.050" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate (SAD Group)</title>
        <time_frame>Baseline (pre-dose Day1), 24h post dose, FU (7 days after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate (SAD Group)</title>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.4"/>
                    <measurement group_id="O2" value="2.8" spread="2.1"/>
                    <measurement group_id="O3" value="1.3" spread="0.5"/>
                    <measurement group_id="O4" value="1.8" spread="1.0"/>
                    <measurement group_id="O5" value="2.0" spread="1.4"/>
                    <measurement group_id="O6" value="3.0" spread="4.0"/>
                    <measurement group_id="O7" value="7.3" spread="8.5"/>
                    <measurement group_id="O8" value="4.0" spread="3.2"/>
                    <measurement group_id="O9" value="5.0" spread="2.8"/>
                    <measurement group_id="O10" value="2.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.5"/>
                    <measurement group_id="O2" value="0.3" spread="1.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="1.0" spread="0.8"/>
                    <measurement group_id="O5" value="0.0" spread="0.8"/>
                    <measurement group_id="O6" value="0.3" spread="1.0"/>
                    <measurement group_id="O7" value="0.3" spread="0.6"/>
                    <measurement group_id="O8" value="3.0" spread="3.6"/>
                    <measurement group_id="O9" value="-0.5" spread="0.7"/>
                    <measurement group_id="O10" value="1.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.2"/>
                    <measurement group_id="O2" value="0.3" spread="1.5"/>
                    <measurement group_id="O3" value="0.8" spread="1.0"/>
                    <measurement group_id="O4" value="0.5" spread="1.7"/>
                    <measurement group_id="O5" value="0.5" spread="1.7"/>
                    <measurement group_id="O6" value="0.0" spread="0.0"/>
                    <measurement group_id="O7" value="-2.3" spread="6.8"/>
                    <measurement group_id="O8" value="0.5" spread="1.0"/>
                    <measurement group_id="O9" value="0.0" spread="0.0"/>
                    <measurement group_id="O10" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate MAD Group</title>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD group: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate MAD Group</title>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.4"/>
                    <measurement group_id="O2" value="3.0" spread="1.8"/>
                    <measurement group_id="O3" value="2.0" spread="1.4"/>
                    <measurement group_id="O4" value="2.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.5"/>
                    <measurement group_id="O2" value="0.8" spread="0.5"/>
                    <measurement group_id="O3" value="0.5" spread="0.6"/>
                    <measurement group_id="O4" value="0.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="5.7"/>
                    <measurement group_id="O2" value="0.8" spread="2.2"/>
                    <measurement group_id="O3" value="2.5" spread="1.7"/>
                    <measurement group_id="O4" value="0.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="8.2"/>
                    <measurement group_id="O2" value="1.3" spread="1.3"/>
                    <measurement group_id="O3" value="1.0" spread="0.8"/>
                    <measurement group_id="O4" value="2.2" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit SAD Group</title>
        <description>Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24 h postdose, FU (7 days after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit SAD Group</title>
          <description>Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>%red cells to the volume of whole blood.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.77" spread="3.35"/>
                    <measurement group_id="O2" value="43.13" spread="2.79"/>
                    <measurement group_id="O3" value="43.10" spread="3.46"/>
                    <measurement group_id="O4" value="44.38" spread="3.28"/>
                    <measurement group_id="O5" value="42.98" spread="1.41"/>
                    <measurement group_id="O6" value="44.35" spread="2.88"/>
                    <measurement group_id="O7" value="44.05" spread="3.17"/>
                    <measurement group_id="O8" value="41.35" spread="1.68"/>
                    <measurement group_id="O9" value="44.35" spread="2.33"/>
                    <measurement group_id="O10" value="42.53" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.28"/>
                    <measurement group_id="O2" value="0.60" spread="2.10"/>
                    <measurement group_id="O3" value="0.75" spread="0.91"/>
                    <measurement group_id="O4" value="1.95" spread="1.41"/>
                    <measurement group_id="O5" value="1.42" spread="2.12"/>
                    <measurement group_id="O6" value="1.03" spread="2.11"/>
                    <measurement group_id="O7" value="1.33" spread="1.80"/>
                    <measurement group_id="O8" value="2.33" spread="1.87"/>
                    <measurement group_id="O9" value="1.90" spread="0.28"/>
                    <measurement group_id="O10" value="0.68" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.70"/>
                    <measurement group_id="O2" value="-0.65" spread="1.37"/>
                    <measurement group_id="O3" value="0.85" spread="1.45"/>
                    <measurement group_id="O4" value="-0.93" spread="1.91"/>
                    <measurement group_id="O5" value="0.10" spread="1.66"/>
                    <measurement group_id="O6" value="-2.02" spread="0.54"/>
                    <measurement group_id="O7" value="-1.15" spread="2.17"/>
                    <measurement group_id="O8" value="0.07" spread="1.41"/>
                    <measurement group_id="O9" value="-0.65" spread="3.04"/>
                    <measurement group_id="O10" value="0.55" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin. SAD</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin. SAD</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>pg/cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.32" spread="1.83"/>
                    <measurement group_id="O2" value="29.70" spread="0.98"/>
                    <measurement group_id="O3" value="30.78" spread="1.71"/>
                    <measurement group_id="O4" value="30.38" spread="0.49"/>
                    <measurement group_id="O5" value="30.00" spread="1.75"/>
                    <measurement group_id="O6" value="29.63" spread="0.68"/>
                    <measurement group_id="O7" value="30.28" spread="1.26"/>
                    <measurement group_id="O8" value="29.80" spread="1.16"/>
                    <measurement group_id="O9" value="30.25" spread="1.77"/>
                    <measurement group_id="O10" value="29.65" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.34"/>
                    <measurement group_id="O2" value="0.23" spread="0.59"/>
                    <measurement group_id="O3" value="0.17" spread="0.26"/>
                    <measurement group_id="O4" value="-0.08" spread="0.26"/>
                    <measurement group_id="O5" value="-0.15" spread="0.13"/>
                    <measurement group_id="O6" value="-0.60" spread="0.80"/>
                    <measurement group_id="O7" value="-0.25" spread="0.37"/>
                    <measurement group_id="O8" value="0.33" spread="0.41"/>
                    <measurement group_id="O9" value="0.25" spread="0.64"/>
                    <measurement group_id="O10" value="0.20" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.15"/>
                    <measurement group_id="O2" value="0.05" spread="0.46"/>
                    <measurement group_id="O3" value="-0.28" spread="0.57"/>
                    <measurement group_id="O4" value="-0.23" spread="0.51"/>
                    <measurement group_id="O5" value="-0.42" spread="0.37"/>
                    <measurement group_id="O6" value="-0.28" spread="0.21"/>
                    <measurement group_id="O7" value="-0.58" spread="0.22"/>
                    <measurement group_id="O8" value="0.12" spread="0.39"/>
                    <measurement group_id="O9" value="-0.15" spread="0.35"/>
                    <measurement group_id="O10" value="-0.08" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin Concentration - SAD</title>
        <description>Erythrocyte mean corpuscular hemoglobin concentration (MCHC) is a measure of the average concentration of hemoglobin per red blood cell. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin Concentration - SAD</title>
          <description>Erythrocyte mean corpuscular hemoglobin concentration (MCHC) is a measure of the average concentration of hemoglobin per red blood cell. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>g/dL RBC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.15" spread="0.34"/>
                    <measurement group_id="O2" value="33.98" spread="1.01"/>
                    <measurement group_id="O3" value="34.18" spread="0.46"/>
                    <measurement group_id="O4" value="34.38" spread="0.84"/>
                    <measurement group_id="O5" value="34.53" spread="0.45"/>
                    <measurement group_id="O6" value="34.33" spread="1.07"/>
                    <measurement group_id="O7" value="34.20" spread="0.65"/>
                    <measurement group_id="O8" value="33.25" spread="0.71"/>
                    <measurement group_id="O9" value="34.70" spread="0.57"/>
                    <measurement group_id="O10" value="34.68" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.32"/>
                    <measurement group_id="O2" value="0.43" spread="0.42"/>
                    <measurement group_id="O3" value="0.00" spread="0.35"/>
                    <measurement group_id="O4" value="-0.27" spread="0.39"/>
                    <measurement group_id="O5" value="-0.17" spread="0.15"/>
                    <measurement group_id="O6" value="-1.05" spread="0.87"/>
                    <measurement group_id="O7" value="-0.20" spread="0.42"/>
                    <measurement group_id="O8" value="0.82" spread="0.29"/>
                    <measurement group_id="O9" value="0.10" spread="0.57"/>
                    <measurement group_id="O10" value="0.45" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.62"/>
                    <measurement group_id="O2" value="0.47" spread="0.42"/>
                    <measurement group_id="O3" value="0.27" spread="0.54"/>
                    <measurement group_id="O4" value="0.18" spread="0.60"/>
                    <measurement group_id="O5" value="-0.05" spread="0.64"/>
                    <measurement group_id="O6" value="0.30" spread="0.48"/>
                    <measurement group_id="O7" value="-0.13" spread="0.61"/>
                    <measurement group_id="O8" value="1.00" spread="0.12"/>
                    <measurement group_id="O9" value="-0.60" spread="0.28"/>
                    <measurement group_id="O10" value="-0.20" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume - SAD</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume - SAD</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.75" spread="5.36"/>
                    <measurement group_id="O2" value="87.52" spread="3.71"/>
                    <measurement group_id="O3" value="90.15" spread="5.73"/>
                    <measurement group_id="O4" value="88.35" spread="2.88"/>
                    <measurement group_id="O5" value="86.93" spread="4.75"/>
                    <measurement group_id="O6" value="86.42" spread="2.83"/>
                    <measurement group_id="O7" value="88.55" spread="4.57"/>
                    <measurement group_id="O8" value="89.73" spread="4.24"/>
                    <measurement group_id="O9" value="87.10" spread="6.65"/>
                    <measurement group_id="O10" value="85.48" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.85"/>
                    <measurement group_id="O2" value="-0.38" spread="1.09"/>
                    <measurement group_id="O3" value="0.35" spread="0.37"/>
                    <measurement group_id="O4" value="0.48" spread="0.41"/>
                    <measurement group_id="O5" value="0.00" spread="0.08"/>
                    <measurement group_id="O6" value="0.85" spread="0.73"/>
                    <measurement group_id="O7" value="-0.27" spread="0.21"/>
                    <measurement group_id="O8" value="-1.33" spread="0.72"/>
                    <measurement group_id="O9" value="0.60" spread="0.28"/>
                    <measurement group_id="O10" value="-0.55" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="1.85"/>
                    <measurement group_id="O2" value="-1.03" spread="0.46"/>
                    <measurement group_id="O3" value="-1.68" spread="0.90"/>
                    <measurement group_id="O4" value="-0.92" spread="1.28"/>
                    <measurement group_id="O5" value="-1.25" spread="1.54"/>
                    <measurement group_id="O6" value="-1.52" spread="0.69"/>
                    <measurement group_id="O7" value="-1.45" spread="1.02"/>
                    <measurement group_id="O8" value="-2.30" spread="1.00"/>
                    <measurement group_id="O9" value="1.10" spread="0.28"/>
                    <measurement group_id="O10" value="0.20" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MAD: Change From Baseline in ECG Results by Time Point: QTcF</title>
        <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple-dose part.&#xD;
QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.</description>
        <time_frame>Baseline, Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD group: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>MAD: Change From Baseline in ECG Results by Time Point: QTcF</title>
          <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple-dose part.&#xD;
QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397.3" spread="18.4"/>
                    <measurement group_id="O2" value="384.3" spread="21.7"/>
                    <measurement group_id="O3" value="388.5" spread="4.7"/>
                    <measurement group_id="O4" value="393.0" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 2h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="7.5"/>
                    <measurement group_id="O2" value="5.5" spread="8.1"/>
                    <measurement group_id="O3" value="7.3" spread="7.0"/>
                    <measurement group_id="O4" value="1.7" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="6.6"/>
                    <measurement group_id="O2" value="0.5" spread="5.7"/>
                    <measurement group_id="O3" value="3.3" spread="13.6"/>
                    <measurement group_id="O4" value="-4.8" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 at 1h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="10.2"/>
                    <measurement group_id="O2" value="-3.0" spread="3.3"/>
                    <measurement group_id="O3" value="-6.5" spread="8.1"/>
                    <measurement group_id="O4" value="-2.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 at 2h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="2.5"/>
                    <measurement group_id="O2" value="-0.3" spread="8.2"/>
                    <measurement group_id="O3" value="-0.8" spread="3.2"/>
                    <measurement group_id="O4" value="-0.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 at 4h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="4.7"/>
                    <measurement group_id="O2" value="-3.8" spread="3.5"/>
                    <measurement group_id="O3" value="-5.8" spread="7.7"/>
                    <measurement group_id="O4" value="3.0" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 BL at 6h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="7.3"/>
                    <measurement group_id="O2" value="2.0" spread="4.7"/>
                    <measurement group_id="O3" value="-7.3" spread="1.9"/>
                    <measurement group_id="O4" value="-0.5" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 at 8h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" spread="3.2"/>
                    <measurement group_id="O2" value="-3.8" spread="6.9"/>
                    <measurement group_id="O3" value="-11.0" spread="5.3"/>
                    <measurement group_id="O4" value="0.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 at 12h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.6"/>
                    <measurement group_id="O2" value="-5.0" spread="3.5"/>
                    <measurement group_id="O3" value="-10.0" spread="4.7"/>
                    <measurement group_id="O4" value="1.7" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="6.6"/>
                    <measurement group_id="O2" value="0.5" spread="5.7"/>
                    <measurement group_id="O3" value="3.3" spread="13.6"/>
                    <measurement group_id="O4" value="-4.8" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="8.6"/>
                    <measurement group_id="O2" value="2.8" spread="6.4"/>
                    <measurement group_id="O3" value="10.5" spread="17.2"/>
                    <measurement group_id="O4" value="-7.5" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="14.6"/>
                    <measurement group_id="O2" value="0.5" spread="13.6"/>
                    <measurement group_id="O3" value="7.3" spread="10.2"/>
                    <measurement group_id="O4" value="-6.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="13.3"/>
                    <measurement group_id="O2" value="2.5" spread="7.2"/>
                    <measurement group_id="O3" value="10.8" spread="6.7"/>
                    <measurement group_id="O4" value="-5.3" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="12.5"/>
                    <measurement group_id="O2" value="-1.5" spread="6.2"/>
                    <measurement group_id="O3" value="7.8" spread="8.0"/>
                    <measurement group_id="O4" value="-8.2" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="11.9"/>
                    <measurement group_id="O2" value="3.0" spread="9.5"/>
                    <measurement group_id="O3" value="13.5" spread="8.7"/>
                    <measurement group_id="O4" value="-8.8" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="5.0"/>
                    <measurement group_id="O2" value="4.0" spread="6.3"/>
                    <measurement group_id="O3" value="-0.5" spread="14.4"/>
                    <measurement group_id="O4" value="6.7" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells 10^3/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.435" spread="0.526"/>
                    <measurement group_id="O2" value="4.773" spread="0.548"/>
                    <measurement group_id="O3" value="4.313" spread="0.418"/>
                    <measurement group_id="O4" value="4.863" spread="0.372"/>
                    <measurement group_id="O5" value="4.395" spread="0.694"/>
                    <measurement group_id="O6" value="4.475" spread="0.733"/>
                    <measurement group_id="O7" value="4.853" spread="0.372"/>
                    <measurement group_id="O8" value="5.118" spread="0.647"/>
                    <measurement group_id="O9" value="5.815" spread="2.072"/>
                    <measurement group_id="O10" value="5.535" spread="1.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.343" spread="0.525"/>
                    <measurement group_id="O2" value="-0.057" spread="0.359"/>
                    <measurement group_id="O3" value="-0.033" spread="0.317"/>
                    <measurement group_id="O4" value="0.160" spread="0.329"/>
                    <measurement group_id="O5" value="0.257" spread="0.529"/>
                    <measurement group_id="O6" value="0.160" spread="0.753"/>
                    <measurement group_id="O7" value="0.528" spread="0.324"/>
                    <measurement group_id="O8" value="0.655" spread="0.666"/>
                    <measurement group_id="O9" value="0.220" spread="0.721"/>
                    <measurement group_id="O10" value="-0.280" spread="0.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.258" spread="0.309"/>
                    <measurement group_id="O2" value="-0.203" spread="0.662"/>
                    <measurement group_id="O3" value="0.288" spread="0.211"/>
                    <measurement group_id="O4" value="-0.073" spread="0.367"/>
                    <measurement group_id="O5" value="0.395" spread="0.617"/>
                    <measurement group_id="O6" value="-0.287" spread="0.618"/>
                    <measurement group_id="O7" value="0.215" spread="0.266"/>
                    <measurement group_id="O8" value="-0.320" spread="0.592"/>
                    <measurement group_id="O9" value="-0.560" spread="1.202"/>
                    <measurement group_id="O10" value="-0.745" spread="1.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1570.0" spread="227.0"/>
                    <measurement group_id="O2" value="1748.3" spread="441.1"/>
                    <measurement group_id="O3" value="1655.0" spread="200.4"/>
                    <measurement group_id="O4" value="1862.5" spread="548.2"/>
                    <measurement group_id="O5" value="1485.0" spread="169.2"/>
                    <measurement group_id="O6" value="1570.0" spread="273.1"/>
                    <measurement group_id="O7" value="1550.0" spread="275.3"/>
                    <measurement group_id="O8" value="1497.5" spread="707.6"/>
                    <measurement group_id="O9" value="2260.0" spread="975.8"/>
                    <measurement group_id="O10" value="1640.0" spread="243.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="223.4"/>
                    <measurement group_id="O2" value="-16.7" spread="347.3"/>
                    <measurement group_id="O3" value="-45.0" spread="192.8"/>
                    <measurement group_id="O4" value="-172.5" spread="227.1"/>
                    <measurement group_id="O5" value="-27.5" spread="58.0"/>
                    <measurement group_id="O6" value="92.5" spread="225.6"/>
                    <measurement group_id="O7" value="287.5" spread="353.7"/>
                    <measurement group_id="O8" value="37.5" spread="159.9"/>
                    <measurement group_id="O9" value="-135.0" spread="261.6"/>
                    <measurement group_id="O10" value="-70.0" spread="177.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7" spread="265.3"/>
                    <measurement group_id="O2" value="-45.0" spread="253.3"/>
                    <measurement group_id="O3" value="180.0" spread="186.5"/>
                    <measurement group_id="O4" value="-92.5" spread="315.7"/>
                    <measurement group_id="O5" value="127.5" spread="425.2"/>
                    <measurement group_id="O6" value="-32.5" spread="174.6"/>
                    <measurement group_id="O7" value="135.0" spread="294.2"/>
                    <measurement group_id="O8" value="-7.5" spread="244.0"/>
                    <measurement group_id="O9" value="-190.0" spread="410.1"/>
                    <measurement group_id="O10" value="-27.5" spread="125.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2276.7" spread="551.2"/>
                    <measurement group_id="O2" value="2296.7" spread="658.7"/>
                    <measurement group_id="O3" value="2117.5" spread="369.2"/>
                    <measurement group_id="O4" value="2365.0" spread="820.8"/>
                    <measurement group_id="O5" value="2380.0" spread="679.0"/>
                    <measurement group_id="O6" value="2197.5" spread="835.9"/>
                    <measurement group_id="O7" value="2565.0" spread="462.6"/>
                    <measurement group_id="O8" value="2360.0" spread="438.1"/>
                    <measurement group_id="O9" value="2280.0" spread="169.7"/>
                    <measurement group_id="O10" value="3192.5" spread="1523.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356.7" spread="336.9"/>
                    <measurement group_id="O2" value="98.3" spread="171.2"/>
                    <measurement group_id="O3" value="7.5" spread="196.7"/>
                    <measurement group_id="O4" value="410.0" spread="593.0"/>
                    <measurement group_id="O5" value="272.5" spread="419.1"/>
                    <measurement group_id="O6" value="165.0" spread="335.5"/>
                    <measurement group_id="O7" value="285.0" spread="155.0"/>
                    <measurement group_id="O8" value="440.0" spread="601.5"/>
                    <measurement group_id="O9" value="445.0" spread="459.6"/>
                    <measurement group_id="O10" value="-122.5" spread="584.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.0" spread="161.8"/>
                    <measurement group_id="O2" value="-16.7" spread="335.4"/>
                    <measurement group_id="O3" value="90.0" spread="183.5"/>
                    <measurement group_id="O4" value="107.5" spread="252.1"/>
                    <measurement group_id="O5" value="255.0" spread="519.0"/>
                    <measurement group_id="O6" value="-167.5" spread="480.7"/>
                    <measurement group_id="O7" value="-12.5" spread="203.5"/>
                    <measurement group_id="O8" value="-382.5" spread="232.9"/>
                    <measurement group_id="O9" value="-205.0" spread="445.5"/>
                    <measurement group_id="O10" value="-557.5" spread="1326.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit MAD Group</title>
        <description>Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD group: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit MAD Group</title>
          <description>Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>% of red cells to volume of whole blood.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.93" spread="1.20"/>
                    <measurement group_id="O2" value="43.40" spread="3.51"/>
                    <measurement group_id="O3" value="45.10" spread="1.33"/>
                    <measurement group_id="O4" value="43.30" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="1.94"/>
                    <measurement group_id="O2" value="1.17" spread="1.69"/>
                    <measurement group_id="O3" value="0.13" spread="0.45"/>
                    <measurement group_id="O4" value="1.70" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="1.24"/>
                    <measurement group_id="O2" value="1.22" spread="3.26"/>
                    <measurement group_id="O3" value="0.10" spread="1.22"/>
                    <measurement group_id="O4" value="1.93" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="1.06"/>
                    <measurement group_id="O2" value="-0.10" spread="3.26"/>
                    <measurement group_id="O3" value="-1.05" spread="0.64"/>
                    <measurement group_id="O4" value="-0.75" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.0" spread="50.1"/>
                    <measurement group_id="O2" value="191.7" spread="109.4"/>
                    <measurement group_id="O3" value="110.0" spread="49.7"/>
                    <measurement group_id="O4" value="137.5" spread="83.4"/>
                    <measurement group_id="O5" value="112.5" spread="36.9"/>
                    <measurement group_id="O6" value="200.0" spread="78.7"/>
                    <measurement group_id="O7" value="245.0" spread="233.6"/>
                    <measurement group_id="O8" value="110.0" spread="71.6"/>
                    <measurement group_id="O9" value="650.0" spread="792.0"/>
                    <measurement group_id="O10" value="152.5" spread="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="16.4"/>
                    <measurement group_id="O2" value="-50.0" spread="40.5"/>
                    <measurement group_id="O3" value="-17.5" spread="9.6"/>
                    <measurement group_id="O4" value="-22.5" spread="42.7"/>
                    <measurement group_id="O5" value="-15.0" spread="12.9"/>
                    <measurement group_id="O6" value="-37.5" spread="47.9"/>
                    <measurement group_id="O7" value="-25.0" spread="33.2"/>
                    <measurement group_id="O8" value="-25.0" spread="26.5"/>
                    <measurement group_id="O9" value="-25.0" spread="7.1"/>
                    <measurement group_id="O10" value="-30.0" spread="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="16.3"/>
                    <measurement group_id="O2" value="-58.3" spread="93.5"/>
                    <measurement group_id="O3" value="-17.5" spread="25.0"/>
                    <measurement group_id="O4" value="-12.5" spread="43.5"/>
                    <measurement group_id="O5" value="-2.5" spread="18.9"/>
                    <measurement group_id="O6" value="-42.5" spread="61.3"/>
                    <measurement group_id="O7" value="77.5" spread="201.6"/>
                    <measurement group_id="O8" value="-20.0" spread="18.3"/>
                    <measurement group_id="O9" value="-125.0" spread="205.1"/>
                    <measurement group_id="O10" value="-42.5" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h, FU (7 days post-dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells 10^3/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.5" spread="45.9"/>
                    <measurement group_id="O2" value="204.0" spread="15.7"/>
                    <measurement group_id="O3" value="193.0" spread="31.9"/>
                    <measurement group_id="O4" value="223.0" spread="21.6"/>
                    <measurement group_id="O5" value="215.8" spread="64.0"/>
                    <measurement group_id="O6" value="203.8" spread="7.0"/>
                    <measurement group_id="O7" value="202.3" spread="54.5"/>
                    <measurement group_id="O8" value="160.1" spread="100.8"/>
                    <measurement group_id="O9" value="204.5" spread="67.2"/>
                    <measurement group_id="O10" value="215.8" spread="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="9.7"/>
                    <measurement group_id="O2" value="4.8" spread="6.1"/>
                    <measurement group_id="O3" value="8.5" spread="12.4"/>
                    <measurement group_id="O4" value="2.3" spread="12.8"/>
                    <measurement group_id="O5" value="3.8" spread="20.3"/>
                    <measurement group_id="O6" value="-14.5" spread="29.7"/>
                    <measurement group_id="O7" value="22.3" spread="13.5"/>
                    <measurement group_id="O8" value="23.0" spread="22.8"/>
                    <measurement group_id="O9" value="4.0" spread="7.1"/>
                    <measurement group_id="O10" value="0.3" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="14.0"/>
                    <measurement group_id="O2" value="22.5" spread="15.7"/>
                    <measurement group_id="O3" value="23.8" spread="7.4"/>
                    <measurement group_id="O4" value="8.5" spread="24.3"/>
                    <measurement group_id="O5" value="16.3" spread="14.5"/>
                    <measurement group_id="O6" value="7.3" spread="7.9"/>
                    <measurement group_id="O7" value="15.8" spread="14.3"/>
                    <measurement group_id="O8" value="21.5" spread="22.4"/>
                    <measurement group_id="O9" value="1.0" spread="15.6"/>
                    <measurement group_id="O10" value="16.3" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value ateach timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post-dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value ateach timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="5.2"/>
                    <measurement group_id="O2" value="25.0" spread="10.5"/>
                    <measurement group_id="O3" value="15.0" spread="5.8"/>
                    <measurement group_id="O4" value="30.0" spread="18.3"/>
                    <measurement group_id="O5" value="15.0" spread="10.0"/>
                    <measurement group_id="O6" value="32.5" spread="15.0"/>
                    <measurement group_id="O7" value="20.0" spread="11.5"/>
                    <measurement group_id="O8" value="22.5" spread="5.0"/>
                    <measurement group_id="O9" value="65.0" spread="63.6"/>
                    <measurement group_id="O10" value="25.0" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="8.4"/>
                    <measurement group_id="O2" value="0.0" spread="8.9"/>
                    <measurement group_id="O3" value="2.5" spread="5.0"/>
                    <measurement group_id="O4" value="-7.5" spread="9.6"/>
                    <measurement group_id="O5" value="0.0" spread="0.0"/>
                    <measurement group_id="O6" value="-5.0" spread="10.0"/>
                    <measurement group_id="O7" value="2.5" spread="5.0"/>
                    <measurement group_id="O8" value="5.0" spread="5.8"/>
                    <measurement group_id="O9" value="-20.0" spread="14.1"/>
                    <measurement group_id="O10" value="-2.5" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="12.6"/>
                    <measurement group_id="O2" value="-1.7" spread="7.5"/>
                    <measurement group_id="O3" value="5.0" spread="5.8"/>
                    <measurement group_id="O4" value="-5.0" spread="10.0"/>
                    <measurement group_id="O5" value="7.5" spread="9.6"/>
                    <measurement group_id="O6" value="-5.0" spread="12.9"/>
                    <measurement group_id="O7" value="20.0" spread="21.6"/>
                    <measurement group_id="O8" value="0.0" spread="8.2"/>
                    <measurement group_id="O9" value="-15.0" spread="21.2"/>
                    <measurement group_id="O10" value="-2.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post-dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445.0" spread="78.2"/>
                    <measurement group_id="O2" value="496.7" spread="71.7"/>
                    <measurement group_id="O3" value="407.5" spread="79.3"/>
                    <measurement group_id="O4" value="455.0" spread="81.9"/>
                    <measurement group_id="O5" value="397.5" spread="133.0"/>
                    <measurement group_id="O6" value="467.5" spread="98.8"/>
                    <measurement group_id="O7" value="462.5" spread="147.1"/>
                    <measurement group_id="O8" value="470.0" spread="87.6"/>
                    <measurement group_id="O9" value="550.0" spread="70.7"/>
                    <measurement group_id="O10" value="512.5" spread="133.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="46.7"/>
                    <measurement group_id="O2" value="-81.7" spread="54.9"/>
                    <measurement group_id="O3" value="20.0" spread="78.3"/>
                    <measurement group_id="O4" value="-45.0" spread="19.3"/>
                    <measurement group_id="O5" value="20.0" spread="122.7"/>
                    <measurement group_id="O6" value="-62.5" spread="185.5"/>
                    <measurement group_id="O7" value="-25.0" spread="112.4"/>
                    <measurement group_id="O8" value="2.5" spread="56.8"/>
                    <measurement group_id="O9" value="-45.0" spread="21.2"/>
                    <measurement group_id="O10" value="-55.0" spread="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.7" spread="91.5"/>
                    <measurement group_id="O2" value="-78.3" spread="74.9"/>
                    <measurement group_id="O3" value="30.0" spread="136.4"/>
                    <measurement group_id="O4" value="-70.0" spread="94.9"/>
                    <measurement group_id="O5" value="5.0" spread="128.2"/>
                    <measurement group_id="O6" value="-42.5" spread="86.6"/>
                    <measurement group_id="O7" value="0.0" spread="94.9"/>
                    <measurement group_id="O8" value="-47.5" spread="63.4"/>
                    <measurement group_id="O9" value="-20.0" spread="127.3"/>
                    <measurement group_id="O10" value="-110.0" spread="128.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.00" spread="0.62"/>
                    <measurement group_id="O2" value="89.32" spread="2.73"/>
                    <measurement group_id="O3" value="86.43" spread="1.29"/>
                    <measurement group_id="O4" value="89.02" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.40"/>
                    <measurement group_id="O2" value="0.52" spread="1.15"/>
                    <measurement group_id="O3" value="0.55" spread="0.71"/>
                    <measurement group_id="O4" value="0.40" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="1.30"/>
                    <measurement group_id="O2" value="-0.43" spread="0.28"/>
                    <measurement group_id="O3" value="0.32" spread="0.90"/>
                    <measurement group_id="O4" value="0.28" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.74"/>
                    <measurement group_id="O2" value="-0.55" spread="0.73"/>
                    <measurement group_id="O3" value="1.22" spread="1.31"/>
                    <measurement group_id="O4" value="0.65" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hemoglobin. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hemoglobin. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.68" spread="0.59"/>
                    <measurement group_id="O2" value="15.23" spread="1.38"/>
                    <measurement group_id="O3" value="15.68" spread="0.64"/>
                    <measurement group_id="O4" value="14.82" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.66"/>
                    <measurement group_id="O2" value="0.42" spread="0.74"/>
                    <measurement group_id="O3" value="0.17" spread="0.22"/>
                    <measurement group_id="O4" value="0.62" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="0.37"/>
                    <measurement group_id="O2" value="0.55" spread="1.22"/>
                    <measurement group_id="O3" value="0.27" spread="0.60"/>
                    <measurement group_id="O4" value="0.75" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.49"/>
                    <measurement group_id="O2" value="-0.05" spread="1.11"/>
                    <measurement group_id="O3" value="-0.38" spread="0.47"/>
                    <measurement group_id="O4" value="-0.35" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. MAD</title>
        <description>Blood samples were collected from participants at the indicated time points for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each time point are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD group: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. MAD</title>
          <description>Blood samples were collected from participants at the indicated time points for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each time point are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells 10^3/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.463" spread="0.579"/>
                    <measurement group_id="O2" value="4.753" spread="0.410"/>
                    <measurement group_id="O3" value="5.378" spread="1.221"/>
                    <measurement group_id="O4" value="4.583" spread="0.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.435" spread="0.631"/>
                    <measurement group_id="O2" value="0.480" spread="0.787"/>
                    <measurement group_id="O3" value="0.895" spread="0.940"/>
                    <measurement group_id="O4" value="0.277" spread="0.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.223" spread="2.237"/>
                    <measurement group_id="O2" value="0.480" spread="0.252"/>
                    <measurement group_id="O3" value="0.795" spread="0.178"/>
                    <measurement group_id="O4" value="0.563" spread="0.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" spread="2.519"/>
                    <measurement group_id="O2" value="0.230" spread="0.870"/>
                    <measurement group_id="O3" value="1.340" spread="0.546"/>
                    <measurement group_id="O4" value="-0.140" spread="0.930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3077.5" spread="569.5"/>
                    <measurement group_id="O2" value="2602.5" spread="582.4"/>
                    <measurement group_id="O3" value="2935.0" spread="966.6"/>
                    <measurement group_id="O4" value="2483.3" spread="583.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-567.5" spread="667.9"/>
                    <measurement group_id="O2" value="350.0" spread="602.4"/>
                    <measurement group_id="O3" value="437.5" spread="505.3"/>
                    <measurement group_id="O4" value="81.7" spread="540.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.0" spread="2079.7"/>
                    <measurement group_id="O2" value="312.5" spread="355.1"/>
                    <measurement group_id="O3" value="537.5" spread="174.6"/>
                    <measurement group_id="O4" value="261.0" spread="634.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.0" spread="2317.4"/>
                    <measurement group_id="O2" value="177.5" spread="827.7"/>
                    <measurement group_id="O3" value="1010.0" spread="622.7"/>
                    <measurement group_id="O4" value="-75.0" spread="532.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin Concentration. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin Concentration. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>g/dL RBC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.28" spread="1.08"/>
                    <measurement group_id="O2" value="35.05" spread="0.37"/>
                    <measurement group_id="O3" value="34.75" spread="0.62"/>
                    <measurement group_id="O4" value="34.23" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.22"/>
                    <measurement group_id="O2" value="0.05" spread="0.62"/>
                    <measurement group_id="O3" value="0.30" spread="0.39"/>
                    <measurement group_id="O4" value="0.08" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.43"/>
                    <measurement group_id="O2" value="0.25" spread="0.26"/>
                    <measurement group_id="O3" value="0.50" spread="0.44"/>
                    <measurement group_id="O4" value="0.17" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.33"/>
                    <measurement group_id="O2" value="0.00" spread="0.27"/>
                    <measurement group_id="O3" value="0.00" spread="0.65"/>
                    <measurement group_id="O4" value="-0.22" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1627.5" spread="656.0"/>
                    <measurement group_id="O2" value="1498.5" spread="125.1"/>
                    <measurement group_id="O3" value="1750.0" spread="187.4"/>
                    <measurement group_id="O4" value="1508.3" spread="317.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" spread="177.8"/>
                    <measurement group_id="O2" value="159.0" spread="188.6"/>
                    <measurement group_id="O3" value="390.0" spread="297.4"/>
                    <measurement group_id="O4" value="215.0" spread="372.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="378.5"/>
                    <measurement group_id="O2" value="124.0" spread="148.8"/>
                    <measurement group_id="O3" value="237.5" spread="208.1"/>
                    <measurement group_id="O4" value="283.3" spread="402.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.0" spread="257.5"/>
                    <measurement group_id="O2" value="39.0" spread="382.3"/>
                    <measurement group_id="O3" value="262.5" spread="220.2"/>
                    <measurement group_id="O4" value="5.0" spread="465.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>pg/cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.80" spread="0.91"/>
                    <measurement group_id="O2" value="31.33" spread="1.24"/>
                    <measurement group_id="O3" value="30.03" spread="0.49"/>
                    <measurement group_id="O4" value="30.47" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.13"/>
                    <measurement group_id="O2" value="0.23" spread="0.39"/>
                    <measurement group_id="O3" value="0.45" spread="0.26"/>
                    <measurement group_id="O4" value="0.20" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.40"/>
                    <measurement group_id="O2" value="0.12" spread="0.22"/>
                    <measurement group_id="O3" value="0.57" spread="0.62"/>
                    <measurement group_id="O4" value="0.25" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.47"/>
                    <measurement group_id="O2" value="-0.20" spread="0.08"/>
                    <measurement group_id="O3" value="0.40" spread="0.41"/>
                    <measurement group_id="O4" value="0.02" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells 10^6/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.588" spread="0.108"/>
                    <measurement group_id="O2" value="4.858" spread="0.380"/>
                    <measurement group_id="O3" value="5.217" spread="0.138"/>
                    <measurement group_id="O4" value="4.873" spread="0.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.313" spread="0.234"/>
                    <measurement group_id="O2" value="0.100" spread="0.193"/>
                    <measurement group_id="O3" value="-0.017" spread="0.060"/>
                    <measurement group_id="O4" value="0.167" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.385" spread="0.139"/>
                    <measurement group_id="O2" value="0.160" spread="0.362"/>
                    <measurement group_id="O3" value="-0.007" spread="0.144"/>
                    <measurement group_id="O4" value="0.198" spread="0.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.075" spread="0.099"/>
                    <measurement group_id="O2" value="0.020" spread="0.350"/>
                    <measurement group_id="O3" value="-0.192" spread="0.145"/>
                    <measurement group_id="O4" value="-0.120" spread="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212.5" spread="79.3"/>
                    <measurement group_id="O2" value="183.5" spread="84.6"/>
                    <measurement group_id="O3" value="127.5" spread="45.7"/>
                    <measurement group_id="O4" value="141.7" spread="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.0" spread="52.3"/>
                    <measurement group_id="O2" value="-31.0" spread="53.2"/>
                    <measurement group_id="O3" value="7.5" spread="20.6"/>
                    <measurement group_id="O4" value="-28.3" spread="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.5" spread="87.3"/>
                    <measurement group_id="O2" value="-28.5" spread="66.0"/>
                    <measurement group_id="O3" value="-10.0" spread="27.1"/>
                    <measurement group_id="O4" value="-22.7" spread="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.5" spread="131.8"/>
                    <measurement group_id="O2" value="31.5" spread="26.5"/>
                    <measurement group_id="O3" value="-17.5" spread="27.5"/>
                    <measurement group_id="O4" value="-45.0" spread="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505.0" spread="44.3"/>
                    <measurement group_id="O2" value="424.0" spread="140.9"/>
                    <measurement group_id="O3" value="530.0" spread="134.9"/>
                    <measurement group_id="O4" value="418.3" spread="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="151.5"/>
                    <measurement group_id="O2" value="-11.5" spread="142.6"/>
                    <measurement group_id="O3" value="57.5" spread="115.0"/>
                    <measurement group_id="O4" value="1.7" spread="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.5" spread="374.6"/>
                    <measurement group_id="O2" value="76.0" spread="95.3"/>
                    <measurement group_id="O3" value="27.5" spread="42.7"/>
                    <measurement group_id="O4" value="24.3" spread="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.5" spread="176.7"/>
                    <measurement group_id="O2" value="-21.5" spread="140.5"/>
                    <measurement group_id="O3" value="82.5" spread="76.8"/>
                    <measurement group_id="O4" value="-43.3" spread="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells 10^3/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.3" spread="24.6"/>
                    <measurement group_id="O2" value="211.5" spread="41.2"/>
                    <measurement group_id="O3" value="199.8" spread="25.6"/>
                    <measurement group_id="O4" value="206.7" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="14.5"/>
                    <measurement group_id="O2" value="17.5" spread="9.5"/>
                    <measurement group_id="O3" value="27.5" spread="8.4"/>
                    <measurement group_id="O4" value="17.3" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" spread="37.6"/>
                    <measurement group_id="O2" value="4.8" spread="22.3"/>
                    <measurement group_id="O3" value="31.3" spread="13.9"/>
                    <measurement group_id="O4" value="29.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8" spread="41.3"/>
                    <measurement group_id="O2" value="5.5" spread="21.9"/>
                    <measurement group_id="O3" value="33.8" spread="20.0"/>
                    <measurement group_id="O4" value="21.7" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="8.2"/>
                    <measurement group_id="O2" value="34.0" spread="10.8"/>
                    <measurement group_id="O3" value="20.0" spread="11.5"/>
                    <measurement group_id="O4" value="23.3" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="17.1"/>
                    <measurement group_id="O2" value="8.5" spread="17.4"/>
                    <measurement group_id="O3" value="2.5" spread="5.0"/>
                    <measurement group_id="O4" value="3.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="20.6"/>
                    <measurement group_id="O2" value="-6.5" spread="17.0"/>
                    <measurement group_id="O3" value="5.0" spread="12.9"/>
                    <measurement group_id="O4" value="4.0" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="15.0"/>
                    <measurement group_id="O2" value="1.0" spread="6.6"/>
                    <measurement group_id="O3" value="2.5" spread="12.6"/>
                    <measurement group_id="O4" value="5.0" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Aspartate Aminotransferase. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Aspartate Aminotransferase. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="5.9"/>
                    <measurement group_id="O2" value="16.8" spread="2.7"/>
                    <measurement group_id="O3" value="19.3" spread="4.3"/>
                    <measurement group_id="O4" value="17.5" spread="3.8"/>
                    <measurement group_id="O5" value="18.3" spread="9.2"/>
                    <measurement group_id="O6" value="20.8" spread="4.4"/>
                    <measurement group_id="O7" value="18.8" spread="6.1"/>
                    <measurement group_id="O8" value="17.0" spread="2.9"/>
                    <measurement group_id="O9" value="19.5" spread="2.1"/>
                    <measurement group_id="O10" value="18.5" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="1.2"/>
                    <measurement group_id="O2" value="0.3" spread="2.1"/>
                    <measurement group_id="O3" value="-0.5" spread="1.3"/>
                    <measurement group_id="O4" value="1.8" spread="3.0"/>
                    <measurement group_id="O5" value="-2.5" spread="4.7"/>
                    <measurement group_id="O6" value="-0.3" spread="1.0"/>
                    <measurement group_id="O7" value="-1.0" spread="3.3"/>
                    <measurement group_id="O8" value="0.5" spread="2.5"/>
                    <measurement group_id="O9" value="-1.0" spread="2.8"/>
                    <measurement group_id="O10" value="-1.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.0"/>
                    <measurement group_id="O2" value="3.3" spread="5.8"/>
                    <measurement group_id="O3" value="2.8" spread="6.2"/>
                    <measurement group_id="O4" value="4.8" spread="7.6"/>
                    <measurement group_id="O5" value="0.3" spread="4.9"/>
                    <measurement group_id="O6" value="0.5" spread="7.6"/>
                    <measurement group_id="O7" value="1.3" spread="3.6"/>
                    <measurement group_id="O8" value="1.0" spread="3.7"/>
                    <measurement group_id="O9" value="3.5" spread="6.4"/>
                    <measurement group_id="O10" value="0.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Protein. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Protein. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" spread="4.9"/>
                    <measurement group_id="O2" value="65.5" spread="5.2"/>
                    <measurement group_id="O3" value="67.0" spread="4.1"/>
                    <measurement group_id="O4" value="67.3" spread="2.2"/>
                    <measurement group_id="O5" value="65.3" spread="5.0"/>
                    <measurement group_id="O6" value="66.0" spread="1.8"/>
                    <measurement group_id="O7" value="66.3" spread="3.5"/>
                    <measurement group_id="O8" value="66.0" spread="1.4"/>
                    <measurement group_id="O9" value="66.5" spread="2.1"/>
                    <measurement group_id="O10" value="66.3" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.7"/>
                    <measurement group_id="O2" value="3.7" spread="3.6"/>
                    <measurement group_id="O3" value="1.5" spread="1.0"/>
                    <measurement group_id="O4" value="3.0" spread="2.4"/>
                    <measurement group_id="O5" value="2.8" spread="4.0"/>
                    <measurement group_id="O6" value="6.0" spread="1.6"/>
                    <measurement group_id="O7" value="3.0" spread="5.0"/>
                    <measurement group_id="O8" value="9.3" spread="4.8"/>
                    <measurement group_id="O9" value="2.5" spread="4.9"/>
                    <measurement group_id="O10" value="2.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.9"/>
                    <measurement group_id="O2" value="3.3" spread="3.1"/>
                    <measurement group_id="O3" value="4.0" spread="2.2"/>
                    <measurement group_id="O4" value="1.8" spread="3.9"/>
                    <measurement group_id="O5" value="3.3" spread="1.7"/>
                    <measurement group_id="O6" value="0.8" spread="1.7"/>
                    <measurement group_id="O7" value="0.0" spread="2.2"/>
                    <measurement group_id="O8" value="4.8" spread="3.3"/>
                    <measurement group_id="O9" value="1.0" spread="1.4"/>
                    <measurement group_id="O10" value="2.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Gamma-GT. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Gamma-GT. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" spread="26.7"/>
                    <measurement group_id="O2" value="19.0" spread="14.1"/>
                    <measurement group_id="O3" value="24.0" spread="20.0"/>
                    <measurement group_id="O4" value="23.0" spread="16.2"/>
                    <measurement group_id="O5" value="12.0" spread="6.8"/>
                    <measurement group_id="O6" value="17.3" spread="12.1"/>
                    <measurement group_id="O7" value="30.0" spread="30.8"/>
                    <measurement group_id="O8" value="21.3" spread="17.2"/>
                    <measurement group_id="O9" value="29.0" spread="14.1"/>
                    <measurement group_id="O10" value="13.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.7"/>
                    <measurement group_id="O2" value="1.2" spread="2.1"/>
                    <measurement group_id="O3" value="0.0" spread="0.8"/>
                    <measurement group_id="O4" value="0.8" spread="1.7"/>
                    <measurement group_id="O5" value="0.3" spread="1.3"/>
                    <measurement group_id="O6" value="1.3" spread="0.5"/>
                    <measurement group_id="O7" value="-0.5" spread="4.4"/>
                    <measurement group_id="O8" value="3.8" spread="3.1"/>
                    <measurement group_id="O9" value="0.0" spread="2.8"/>
                    <measurement group_id="O10" value="0.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="13.8"/>
                    <measurement group_id="O2" value="10.0" spread="16.1"/>
                    <measurement group_id="O3" value="-1.3" spread="4.5"/>
                    <measurement group_id="O4" value="13.8" spread="18.4"/>
                    <measurement group_id="O5" value="2.5" spread="2.4"/>
                    <measurement group_id="O6" value="11.3" spread="20.5"/>
                    <measurement group_id="O7" value="-7.3" spread="15.6"/>
                    <measurement group_id="O8" value="1.8" spread="2.5"/>
                    <measurement group_id="O9" value="3.5" spread="3.5"/>
                    <measurement group_id="O10" value="1.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alkaline Phosphatase. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alkaline Phosphatase. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" spread="18.6"/>
                    <measurement group_id="O2" value="64.0" spread="19.8"/>
                    <measurement group_id="O3" value="66.0" spread="18.5"/>
                    <measurement group_id="O4" value="75.0" spread="32.2"/>
                    <measurement group_id="O5" value="66.0" spread="25.0"/>
                    <measurement group_id="O6" value="68.3" spread="28.0"/>
                    <measurement group_id="O7" value="53.3" spread="10.2"/>
                    <measurement group_id="O8" value="49.0" spread="8.9"/>
                    <measurement group_id="O9" value="54.5" spread="2.1"/>
                    <measurement group_id="O10" value="62.3" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.0"/>
                    <measurement group_id="O2" value="1.7" spread="3.5"/>
                    <measurement group_id="O3" value="1.0" spread="2.8"/>
                    <measurement group_id="O4" value="-1.8" spread="8.1"/>
                    <measurement group_id="O5" value="1.0" spread="4.7"/>
                    <measurement group_id="O6" value="3.8" spread="4.6"/>
                    <measurement group_id="O7" value="1.3" spread="3.6"/>
                    <measurement group_id="O8" value="6.8" spread="3.5"/>
                    <measurement group_id="O9" value="2.0" spread="2.8"/>
                    <measurement group_id="O10" value="0.8" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="9.0"/>
                    <measurement group_id="O2" value="1.7" spread="6.3"/>
                    <measurement group_id="O3" value="1.8" spread="3.5"/>
                    <measurement group_id="O4" value="-3.8" spread="18.2"/>
                    <measurement group_id="O5" value="1.5" spread="3.4"/>
                    <measurement group_id="O6" value="-1.5" spread="11.3"/>
                    <measurement group_id="O7" value="-2.0" spread="5.4"/>
                    <measurement group_id="O8" value="4.3" spread="1.5"/>
                    <measurement group_id="O9" value="2.0" spread="2.8"/>
                    <measurement group_id="O10" value="-0.8" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.927" spread="0.058"/>
                    <measurement group_id="O2" value="0.768" spread="0.108"/>
                    <measurement group_id="O3" value="0.903" spread="0.028"/>
                    <measurement group_id="O4" value="0.810" spread="0.091"/>
                    <measurement group_id="O5" value="0.838" spread="0.035"/>
                    <measurement group_id="O6" value="0.735" spread="0.108"/>
                    <measurement group_id="O7" value="0.918" spread="0.043"/>
                    <measurement group_id="O8" value="0.838" spread="0.213"/>
                    <measurement group_id="O9" value="0.935" spread="0.078"/>
                    <measurement group_id="O10" value="0.863" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="0.050"/>
                    <measurement group_id="O2" value="0.067" spread="0.033"/>
                    <measurement group_id="O3" value="0.080" spread="0.054"/>
                    <measurement group_id="O4" value="0.053" spread="0.076"/>
                    <measurement group_id="O5" value="0.040" spread="0.041"/>
                    <measurement group_id="O6" value="0.115" spread="0.025"/>
                    <measurement group_id="O7" value="0.090" spread="0.043"/>
                    <measurement group_id="O8" value="0.075" spread="0.112"/>
                    <measurement group_id="O9" value="0.015" spread="0.106"/>
                    <measurement group_id="O10" value="0.038" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.048"/>
                    <measurement group_id="O2" value="0.065" spread="0.048"/>
                    <measurement group_id="O3" value="0.012" spread="0.039"/>
                    <measurement group_id="O4" value="0.073" spread="0.056"/>
                    <measurement group_id="O5" value="0.088" spread="0.068"/>
                    <measurement group_id="O6" value="0.063" spread="0.028"/>
                    <measurement group_id="O7" value="-0.020" spread="0.096"/>
                    <measurement group_id="O8" value="-0.017" spread="0.085"/>
                    <measurement group_id="O9" value="-0.080" spread="0.071"/>
                    <measurement group_id="O10" value="0.063" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Chloride. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Chloride. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.7" spread="2.7"/>
                    <measurement group_id="O2" value="104.0" spread="1.7"/>
                    <measurement group_id="O3" value="103.8" spread="1.7"/>
                    <measurement group_id="O4" value="104.0" spread="0.8"/>
                    <measurement group_id="O5" value="102.3" spread="2.4"/>
                    <measurement group_id="O6" value="103.0" spread="1.4"/>
                    <measurement group_id="O7" value="103.3" spread="1.5"/>
                    <measurement group_id="O8" value="103.8" spread="1.7"/>
                    <measurement group_id="O9" value="100.5" spread="2.1"/>
                    <measurement group_id="O10" value="101.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.4"/>
                    <measurement group_id="O2" value="-2.5" spread="1.4"/>
                    <measurement group_id="O3" value="-1.5" spread="2.5"/>
                    <measurement group_id="O4" value="-3.5" spread="0.6"/>
                    <measurement group_id="O5" value="0.0" spread="1.8"/>
                    <measurement group_id="O6" value="-2.8" spread="1.0"/>
                    <measurement group_id="O7" value="-1.3" spread="1.0"/>
                    <measurement group_id="O8" value="-3.5" spread="1.7"/>
                    <measurement group_id="O9" value="2.0" spread="0.0"/>
                    <measurement group_id="O10" value="-0.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="3.5"/>
                    <measurement group_id="O2" value="-3.2" spread="2.2"/>
                    <measurement group_id="O3" value="-2.5" spread="2.1"/>
                    <measurement group_id="O4" value="-3.5" spread="1.3"/>
                    <measurement group_id="O5" value="-0.8" spread="2.2"/>
                    <measurement group_id="O6" value="-2.3" spread="2.2"/>
                    <measurement group_id="O7" value="-0.8" spread="3.5"/>
                    <measurement group_id="O8" value="-3.0" spread="0.0"/>
                    <measurement group_id="O9" value="3.5" spread="3.5"/>
                    <measurement group_id="O10" value="0.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Bilirubin. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Bilirubin. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.32"/>
                    <measurement group_id="O2" value="0.75" spread="0.60"/>
                    <measurement group_id="O3" value="1.03" spread="0.83"/>
                    <measurement group_id="O4" value="0.68" spread="0.33"/>
                    <measurement group_id="O5" value="1.18" spread="1.03"/>
                    <measurement group_id="O6" value="0.53" spread="0.13"/>
                    <measurement group_id="O7" value="0.63" spread="0.22"/>
                    <measurement group_id="O8" value="0.31" spread="0.19"/>
                    <measurement group_id="O9" value="0.45" spread="0.21"/>
                    <measurement group_id="O10" value="1.10" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.26"/>
                    <measurement group_id="O2" value="0.12" spread="0.08"/>
                    <measurement group_id="O3" value="0.40" spread="0.08"/>
                    <measurement group_id="O4" value="0.38" spread="0.13"/>
                    <measurement group_id="O5" value="-0.00" spread="0.18"/>
                    <measurement group_id="O6" value="0.28" spread="0.10"/>
                    <measurement group_id="O7" value="-0.03" spread="0.15"/>
                    <measurement group_id="O8" value="0.31" spread="0.09"/>
                    <measurement group_id="O9" value="0.15" spread="0.07"/>
                    <measurement group_id="O10" value="0.27" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.42"/>
                    <measurement group_id="O2" value="-0.02" spread="0.40"/>
                    <measurement group_id="O3" value="0.05" spread="0.13"/>
                    <measurement group_id="O4" value="0.13" spread="0.13"/>
                    <measurement group_id="O5" value="-0.18" spread="0.33"/>
                    <measurement group_id="O6" value="0.20" spread="0.18"/>
                    <measurement group_id="O7" value="0.00" spread="0.29"/>
                    <measurement group_id="O8" value="0.21" spread="0.10"/>
                    <measurement group_id="O9" value="0.10" spread="0.14"/>
                    <measurement group_id="O10" value="-0.10" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alanine Aminotransferase. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alanine Aminotransferase. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="11.3"/>
                    <measurement group_id="O2" value="17.2" spread="6.9"/>
                    <measurement group_id="O3" value="19.3" spread="3.2"/>
                    <measurement group_id="O4" value="20.0" spread="10.1"/>
                    <measurement group_id="O5" value="15.0" spread="6.9"/>
                    <measurement group_id="O6" value="19.3" spread="6.6"/>
                    <measurement group_id="O7" value="22.8" spread="12.8"/>
                    <measurement group_id="O8" value="17.8" spread="6.8"/>
                    <measurement group_id="O9" value="19.0" spread="1.4"/>
                    <measurement group_id="O10" value="15.0" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.2"/>
                    <measurement group_id="O2" value="-0.3" spread="3.2"/>
                    <measurement group_id="O3" value="0.8" spread="2.9"/>
                    <measurement group_id="O4" value="-1.3" spread="3.5"/>
                    <measurement group_id="O5" value="1.3" spread="1.3"/>
                    <measurement group_id="O6" value="-0.3" spread="2.8"/>
                    <measurement group_id="O7" value="-2.0" spread="3.6"/>
                    <measurement group_id="O8" value="0.3" spread="3.9"/>
                    <measurement group_id="O9" value="1.5" spread="2.1"/>
                    <measurement group_id="O10" value="1.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="4.5"/>
                    <measurement group_id="O2" value="5.7" spread="17.7"/>
                    <measurement group_id="O3" value="2.3" spread="7.8"/>
                    <measurement group_id="O4" value="8.3" spread="18.0"/>
                    <measurement group_id="O5" value="1.8" spread="2.6"/>
                    <measurement group_id="O6" value="6.0" spread="21.5"/>
                    <measurement group_id="O7" value="-2.3" spread="5.7"/>
                    <measurement group_id="O8" value="-1.0" spread="2.9"/>
                    <measurement group_id="O9" value="7.5" spread="9.2"/>
                    <measurement group_id="O10" value="1.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine Kinase. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine Kinase. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.2" spread="39.3"/>
                    <measurement group_id="O2" value="78.7" spread="5.9"/>
                    <measurement group_id="O3" value="181.8" spread="59.3"/>
                    <measurement group_id="O4" value="78.8" spread="13.4"/>
                    <measurement group_id="O5" value="209.3" spread="223.6"/>
                    <measurement group_id="O6" value="82.3" spread="28.0"/>
                    <measurement group_id="O7" value="68.5" spread="49.5"/>
                    <measurement group_id="O8" value="89.5" spread="45.4"/>
                    <measurement group_id="O9" value="82.5" spread="89.8"/>
                    <measurement group_id="O10" value="81.3" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.3" spread="23.1"/>
                    <measurement group_id="O2" value="-14.0" spread="3.3"/>
                    <measurement group_id="O3" value="-51.0" spread="34.6"/>
                    <measurement group_id="O4" value="-12.8" spread="1.9"/>
                    <measurement group_id="O5" value="-97.8" spread="137.1"/>
                    <measurement group_id="O6" value="-15.5" spread="14.1"/>
                    <measurement group_id="O7" value="-14.0" spread="23.6"/>
                    <measurement group_id="O8" value="-14.8" spread="26.9"/>
                    <measurement group_id="O9" value="-31.5" spread="43.1"/>
                    <measurement group_id="O10" value="-14.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="43.7"/>
                    <measurement group_id="O2" value="16.7" spread="35.7"/>
                    <measurement group_id="O3" value="-17.3" spread="88.6"/>
                    <measurement group_id="O4" value="24.5" spread="39.4"/>
                    <measurement group_id="O5" value="-110.0" spread="173.1"/>
                    <measurement group_id="O6" value="6.0" spread="7.5"/>
                    <measurement group_id="O7" value="15.8" spread="16.9"/>
                    <measurement group_id="O8" value="7.0" spread="61.9"/>
                    <measurement group_id="O9" value="21.5" spread="17.7"/>
                    <measurement group_id="O10" value="18.0" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Urea. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Urea. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="9.3"/>
                    <measurement group_id="O2" value="24.7" spread="4.5"/>
                    <measurement group_id="O3" value="30.0" spread="8.4"/>
                    <measurement group_id="O4" value="26.0" spread="7.3"/>
                    <measurement group_id="O5" value="24.0" spread="2.4"/>
                    <measurement group_id="O6" value="25.3" spread="4.1"/>
                    <measurement group_id="O7" value="29.3" spread="10.6"/>
                    <measurement group_id="O8" value="34.8" spread="7.7"/>
                    <measurement group_id="O9" value="38.5" spread="6.4"/>
                    <measurement group_id="O10" value="25.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="3.9"/>
                    <measurement group_id="O2" value="0.2" spread="4.4"/>
                    <measurement group_id="O3" value="-2.5" spread="5.0"/>
                    <measurement group_id="O4" value="-0.3" spread="2.5"/>
                    <measurement group_id="O5" value="0.0" spread="2.8"/>
                    <measurement group_id="O6" value="-0.5" spread="5.2"/>
                    <measurement group_id="O7" value="-1.0" spread="4.7"/>
                    <measurement group_id="O8" value="-4.0" spread="8.6"/>
                    <measurement group_id="O9" value="-9.0" spread="1.4"/>
                    <measurement group_id="O10" value="-0.5" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="7.1"/>
                    <measurement group_id="O2" value="0.5" spread="7.7"/>
                    <measurement group_id="O3" value="-0.8" spread="3.9"/>
                    <measurement group_id="O4" value="2.3" spread="7.7"/>
                    <measurement group_id="O5" value="0.3" spread="4.5"/>
                    <measurement group_id="O6" value="-2.3" spread="7.3"/>
                    <measurement group_id="O7" value="-0.3" spread="5.4"/>
                    <measurement group_id="O8" value="-6.8" spread="11.8"/>
                    <measurement group_id="O9" value="-8.0" spread="4.2"/>
                    <measurement group_id="O10" value="-1.5" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Sodium. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Sodium. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.8" spread="1.0"/>
                    <measurement group_id="O2" value="142.5" spread="1.2"/>
                    <measurement group_id="O3" value="141.5" spread="0.6"/>
                    <measurement group_id="O4" value="142.8" spread="1.0"/>
                    <measurement group_id="O5" value="141.5" spread="1.7"/>
                    <measurement group_id="O6" value="142.0" spread="0.8"/>
                    <measurement group_id="O7" value="142.3" spread="1.3"/>
                    <measurement group_id="O8" value="143.3" spread="1.0"/>
                    <measurement group_id="O9" value="139.5" spread="0.7"/>
                    <measurement group_id="O10" value="140.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.6"/>
                    <measurement group_id="O2" value="-0.7" spread="0.8"/>
                    <measurement group_id="O3" value="-0.3" spread="2.2"/>
                    <measurement group_id="O4" value="-2.0" spread="1.4"/>
                    <measurement group_id="O5" value="-0.8" spread="2.2"/>
                    <measurement group_id="O6" value="-1.0" spread="0.8"/>
                    <measurement group_id="O7" value="0.5" spread="0.6"/>
                    <measurement group_id="O8" value="-1.3" spread="1.0"/>
                    <measurement group_id="O9" value="2.5" spread="2.1"/>
                    <measurement group_id="O10" value="1.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.4"/>
                    <measurement group_id="O2" value="-1.8" spread="2.0"/>
                    <measurement group_id="O3" value="0.0" spread="2.7"/>
                    <measurement group_id="O4" value="-2.3" spread="2.2"/>
                    <measurement group_id="O5" value="0.8" spread="1.3"/>
                    <measurement group_id="O6" value="-2.0" spread="0.8"/>
                    <measurement group_id="O7" value="0.5" spread="2.4"/>
                    <measurement group_id="O8" value="-2.8" spread="1.3"/>
                    <measurement group_id="O9" value="4.5" spread="0.7"/>
                    <measurement group_id="O10" value="1.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Potassium. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Potassium. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" spread="0.18"/>
                    <measurement group_id="O2" value="4.27" spread="0.18"/>
                    <measurement group_id="O3" value="4.25" spread="0.13"/>
                    <measurement group_id="O4" value="4.18" spread="0.25"/>
                    <measurement group_id="O5" value="4.03" spread="0.19"/>
                    <measurement group_id="O6" value="4.33" spread="0.13"/>
                    <measurement group_id="O7" value="4.28" spread="0.32"/>
                    <measurement group_id="O8" value="4.50" spread="0.18"/>
                    <measurement group_id="O9" value="4.00" spread="0.00"/>
                    <measurement group_id="O10" value="4.20" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.18"/>
                    <measurement group_id="O2" value="0.17" spread="0.21"/>
                    <measurement group_id="O3" value="0.07" spread="0.31"/>
                    <measurement group_id="O4" value="0.23" spread="0.33"/>
                    <measurement group_id="O5" value="0.30" spread="0.22"/>
                    <measurement group_id="O6" value="-0.05" spread="0.26"/>
                    <measurement group_id="O7" value="0.12" spread="0.10"/>
                    <measurement group_id="O8" value="-0.10" spread="0.16"/>
                    <measurement group_id="O9" value="0.25" spread="0.07"/>
                    <measurement group_id="O10" value="0.15" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.10"/>
                    <measurement group_id="O2" value="0.10" spread="0.26"/>
                    <measurement group_id="O3" value="0.30" spread="0.22"/>
                    <measurement group_id="O4" value="0.20" spread="0.29"/>
                    <measurement group_id="O5" value="0.50" spread="0.22"/>
                    <measurement group_id="O6" value="0.10" spread="0.27"/>
                    <measurement group_id="O7" value="0.08" spread="0.36"/>
                    <measurement group_id="O8" value="-0.05" spread="0.10"/>
                    <measurement group_id="O9" value="0.30" spread="0.14"/>
                    <measurement group_id="O10" value="0.33" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Phosphate. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Phosphate. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.042" spread="0.066"/>
                    <measurement group_id="O2" value="0.998" spread="0.122"/>
                    <measurement group_id="O3" value="1.120" spread="0.117"/>
                    <measurement group_id="O4" value="1.085" spread="0.133"/>
                    <measurement group_id="O5" value="1.023" spread="0.081"/>
                    <measurement group_id="O6" value="0.983" spread="0.165"/>
                    <measurement group_id="O7" value="1.088" spread="0.142"/>
                    <measurement group_id="O8" value="1.128" spread="0.193"/>
                    <measurement group_id="O9" value="1.410" spread="0.552"/>
                    <measurement group_id="O10" value="1.105" spread="0.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.126"/>
                    <measurement group_id="O2" value="-0.045" spread="0.094"/>
                    <measurement group_id="O3" value="-0.035" spread="0.169"/>
                    <measurement group_id="O4" value="-0.133" spread="0.105"/>
                    <measurement group_id="O5" value="0.045" spread="0.172"/>
                    <measurement group_id="O6" value="-0.060" spread="0.111"/>
                    <measurement group_id="O7" value="0.032" spread="0.116"/>
                    <measurement group_id="O8" value="-0.090" spread="0.164"/>
                    <measurement group_id="O9" value="-0.180" spread="0.999"/>
                    <measurement group_id="O10" value="-0.015" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.116"/>
                    <measurement group_id="O2" value="0.030" spread="0.172"/>
                    <measurement group_id="O3" value="-0.077" spread="0.126"/>
                    <measurement group_id="O4" value="-0.018" spread="0.182"/>
                    <measurement group_id="O5" value="0.003" spread="0.046"/>
                    <measurement group_id="O6" value="-0.070" spread="0.153"/>
                    <measurement group_id="O7" value="-0.090" spread="0.121"/>
                    <measurement group_id="O8" value="-0.105" spread="0.135"/>
                    <measurement group_id="O9" value="-0.395" spread="0.205"/>
                    <measurement group_id="O10" value="-0.080" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Calcium (Corrected for Albumin). SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Calcium (Corrected for Albumin). SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.380" spread="0.073"/>
                    <measurement group_id="O2" value="2.303" spread="0.087"/>
                    <measurement group_id="O3" value="2.290" spread="0.114"/>
                    <measurement group_id="O4" value="2.288" spread="0.030"/>
                    <measurement group_id="O5" value="2.373" spread="0.116"/>
                    <measurement group_id="O6" value="2.358" spread="0.069"/>
                    <measurement group_id="O7" value="2.353" spread="0.102"/>
                    <measurement group_id="O8" value="2.323" spread="0.044"/>
                    <measurement group_id="O9" value="2.340" spread="0.000"/>
                    <measurement group_id="O10" value="2.360" spread="0.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.045"/>
                    <measurement group_id="O2" value="0.095" spread="0.066"/>
                    <measurement group_id="O3" value="0.098" spread="0.050"/>
                    <measurement group_id="O4" value="0.093" spread="0.028"/>
                    <measurement group_id="O5" value="0.058" spread="0.105"/>
                    <measurement group_id="O6" value="0.085" spread="0.059"/>
                    <measurement group_id="O7" value="0.078" spread="0.075"/>
                    <measurement group_id="O8" value="0.148" spread="0.055"/>
                    <measurement group_id="O9" value="-0.005" spread="0.021"/>
                    <measurement group_id="O10" value="0.075" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.041"/>
                    <measurement group_id="O2" value="0.062" spread="0.075"/>
                    <measurement group_id="O3" value="0.085" spread="0.070"/>
                    <measurement group_id="O4" value="0.073" spread="0.098"/>
                    <measurement group_id="O5" value="0.042" spread="0.030"/>
                    <measurement group_id="O6" value="-0.032" spread="0.006"/>
                    <measurement group_id="O7" value="-0.005" spread="0.033"/>
                    <measurement group_id="O8" value="0.090" spread="0.059"/>
                    <measurement group_id="O9" value="-0.065" spread="0.049"/>
                    <measurement group_id="O10" value="0.055" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Uric Acid. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Uric Acid. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" spread="0.84"/>
                    <measurement group_id="O2" value="4.85" spread="0.84"/>
                    <measurement group_id="O3" value="5.75" spread="0.42"/>
                    <measurement group_id="O4" value="4.80" spread="0.37"/>
                    <measurement group_id="O5" value="5.48" spread="0.82"/>
                    <measurement group_id="O6" value="4.75" spread="0.79"/>
                    <measurement group_id="O7" value="5.48" spread="1.07"/>
                    <measurement group_id="O8" value="5.10" spread="0.96"/>
                    <measurement group_id="O9" value="5.45" spread="0.21"/>
                    <measurement group_id="O10" value="5.50" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.40"/>
                    <measurement group_id="O2" value="-0.13" spread="0.23"/>
                    <measurement group_id="O3" value="-0.28" spread="0.25"/>
                    <measurement group_id="O4" value="-0.20" spread="0.24"/>
                    <measurement group_id="O5" value="-0.30" spread="0.12"/>
                    <measurement group_id="O6" value="-0.25" spread="0.24"/>
                    <measurement group_id="O7" value="-0.20" spread="0.32"/>
                    <measurement group_id="O8" value="0.15" spread="0.42"/>
                    <measurement group_id="O9" value="-0.60" spread="0.28"/>
                    <measurement group_id="O10" value="-0.28" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.26"/>
                    <measurement group_id="O2" value="0.32" spread="0.50"/>
                    <measurement group_id="O3" value="0.22" spread="0.79"/>
                    <measurement group_id="O4" value="0.40" spread="0.43"/>
                    <measurement group_id="O5" value="0.35" spread="0.53"/>
                    <measurement group_id="O6" value="0.30" spread="0.08"/>
                    <measurement group_id="O7" value="0.18" spread="0.68"/>
                    <measurement group_id="O8" value="0.23" spread="0.22"/>
                    <measurement group_id="O9" value="0.40" spread="0.28"/>
                    <measurement group_id="O10" value="0.33" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triiodothyronine (T3). SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triiodothyronine (T3). SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="0.35"/>
                    <measurement group_id="O2" value="3.23" spread="0.12"/>
                    <measurement group_id="O3" value="3.73" spread="0.21"/>
                    <measurement group_id="O4" value="3.40" spread="0.22"/>
                    <measurement group_id="O5" value="3.48" spread="0.30"/>
                    <measurement group_id="O6" value="3.18" spread="0.17"/>
                    <measurement group_id="O7" value="3.18" spread="0.17"/>
                    <measurement group_id="O8" value="3.33" spread="0.19"/>
                    <measurement group_id="O9" value="3.60" spread="0.14"/>
                    <measurement group_id="O10" value="3.63" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.28"/>
                    <measurement group_id="O2" value="-0.10" spread="0.24"/>
                    <measurement group_id="O3" value="-0.22" spread="0.17"/>
                    <measurement group_id="O4" value="0.05" spread="0.31"/>
                    <measurement group_id="O5" value="-0.07" spread="0.10"/>
                    <measurement group_id="O6" value="-0.23" spread="0.10"/>
                    <measurement group_id="O7" value="-0.23" spread="0.36"/>
                    <measurement group_id="O8" value="-0.13" spread="0.15"/>
                    <measurement group_id="O9" value="-0.40" spread="0.00"/>
                    <measurement group_id="O10" value="-0.25" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.28"/>
                    <measurement group_id="O2" value="0.42" spread="0.23"/>
                    <measurement group_id="O3" value="-0.23" spread="0.13"/>
                    <measurement group_id="O4" value="0.30" spread="0.23"/>
                    <measurement group_id="O5" value="-0.13" spread="0.17"/>
                    <measurement group_id="O6" value="0.50" spread="0.34"/>
                    <measurement group_id="O7" value="0.05" spread="0.13"/>
                    <measurement group_id="O8" value="0.20" spread="0.08"/>
                    <measurement group_id="O9" value="-0.30" spread="0.14"/>
                    <measurement group_id="O10" value="-0.28" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lipase. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lipase. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" spread="8.2"/>
                    <measurement group_id="O2" value="34.8" spread="16.2"/>
                    <measurement group_id="O3" value="39.0" spread="9.8"/>
                    <measurement group_id="O4" value="29.3" spread="12.7"/>
                    <measurement group_id="O5" value="27.3" spread="7.5"/>
                    <measurement group_id="O6" value="33.0" spread="9.2"/>
                    <measurement group_id="O7" value="30.0" spread="8.0"/>
                    <measurement group_id="O8" value="25.5" spread="6.2"/>
                    <measurement group_id="O9" value="42.0" spread="14.1"/>
                    <measurement group_id="O10" value="31.1" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="3.1"/>
                    <measurement group_id="O2" value="-7.5" spread="18.5"/>
                    <measurement group_id="O3" value="-6.3" spread="6.8"/>
                    <measurement group_id="O4" value="-1.8" spread="2.9"/>
                    <measurement group_id="O5" value="1.3" spread="0.5"/>
                    <measurement group_id="O6" value="7.3" spread="16.5"/>
                    <measurement group_id="O7" value="-1.3" spread="3.4"/>
                    <measurement group_id="O8" value="-4.8" spread="5.1"/>
                    <measurement group_id="O9" value="-0.5" spread="2.1"/>
                    <measurement group_id="O10" value="-2.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.3"/>
                    <measurement group_id="O2" value="-1.0" spread="5.5"/>
                    <measurement group_id="O3" value="-4.5" spread="12.4"/>
                    <measurement group_id="O4" value="8.0" spread="27.2"/>
                    <measurement group_id="O5" value="1.5" spread="3.0"/>
                    <measurement group_id="O6" value="-5.0" spread="3.7"/>
                    <measurement group_id="O7" value="-2.0" spread="6.5"/>
                    <measurement group_id="O8" value="9.3" spread="19.8"/>
                    <measurement group_id="O9" value="-7.0" spread="4.2"/>
                    <measurement group_id="O10" value="-2.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: (Fasting) Glucose. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: (Fasting) Glucose. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="7.3"/>
                    <measurement group_id="O2" value="86.8" spread="8.9"/>
                    <measurement group_id="O3" value="84.8" spread="7.4"/>
                    <measurement group_id="O4" value="88.5" spread="12.2"/>
                    <measurement group_id="O5" value="77.8" spread="5.7"/>
                    <measurement group_id="O6" value="86.3" spread="9.4"/>
                    <measurement group_id="O7" value="87.0" spread="4.2"/>
                    <measurement group_id="O8" value="95.5" spread="18.7"/>
                    <measurement group_id="O9" value="84.0" spread="5.7"/>
                    <measurement group_id="O10" value="78.8" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="3.2"/>
                    <measurement group_id="O2" value="1.2" spread="5.2"/>
                    <measurement group_id="O3" value="2.0" spread="3.7"/>
                    <measurement group_id="O4" value="-2.0" spread="3.2"/>
                    <measurement group_id="O5" value="7.0" spread="4.5"/>
                    <measurement group_id="O6" value="-1.0" spread="1.4"/>
                    <measurement group_id="O7" value="0.5" spread="3.1"/>
                    <measurement group_id="O8" value="-2.3" spread="1.0"/>
                    <measurement group_id="O9" value="4.0" spread="1.4"/>
                    <measurement group_id="O10" value="3.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="7.0"/>
                    <measurement group_id="O2" value="5.5" spread="6.9"/>
                    <measurement group_id="O3" value="-0.3" spread="7.7"/>
                    <measurement group_id="O4" value="6.3" spread="6.7"/>
                    <measurement group_id="O5" value="7.3" spread="6.2"/>
                    <measurement group_id="O6" value="0.5" spread="5.9"/>
                    <measurement group_id="O7" value="-1.3" spread="5.4"/>
                    <measurement group_id="O8" value="-1.5" spread="1.7"/>
                    <measurement group_id="O9" value="2.0" spread="8.5"/>
                    <measurement group_id="O10" value="6.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Human Serum Albumin. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Human Serum Albumin. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="3.1"/>
                    <measurement group_id="O2" value="45.0" spread="2.8"/>
                    <measurement group_id="O3" value="45.3" spread="3.9"/>
                    <measurement group_id="O4" value="45.0" spread="1.2"/>
                    <measurement group_id="O5" value="45.3" spread="3.4"/>
                    <measurement group_id="O6" value="46.0" spread="1.4"/>
                    <measurement group_id="O7" value="44.0" spread="1.2"/>
                    <measurement group_id="O8" value="44.3" spread="1.5"/>
                    <measurement group_id="O9" value="44.0" spread="1.4"/>
                    <measurement group_id="O10" value="45.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.2"/>
                    <measurement group_id="O2" value="1.7" spread="1.5"/>
                    <measurement group_id="O3" value="0.3" spread="1.5"/>
                    <measurement group_id="O4" value="2.0" spread="2.6"/>
                    <measurement group_id="O5" value="1.5" spread="3.7"/>
                    <measurement group_id="O6" value="3.5" spread="1.3"/>
                    <measurement group_id="O7" value="1.5" spread="3.1"/>
                    <measurement group_id="O8" value="5.3" spread="2.6"/>
                    <measurement group_id="O9" value="0.5" spread="2.1"/>
                    <measurement group_id="O10" value="0.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.8"/>
                    <measurement group_id="O2" value="2.0" spread="1.4"/>
                    <measurement group_id="O3" value="2.3" spread="1.5"/>
                    <measurement group_id="O4" value="2.0" spread="2.8"/>
                    <measurement group_id="O5" value="1.0" spread="1.2"/>
                    <measurement group_id="O6" value="0.5" spread="1.3"/>
                    <measurement group_id="O7" value="0.0" spread="0.8"/>
                    <measurement group_id="O8" value="3.5" spread="2.1"/>
                    <measurement group_id="O9" value="0.0" spread="0.0"/>
                    <measurement group_id="O10" value="05" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Cholesterol. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Cholesterol. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.0" spread="47.7"/>
                    <measurement group_id="O2" value="151.0" spread="26.6"/>
                    <measurement group_id="O3" value="146.3" spread="37.5"/>
                    <measurement group_id="O4" value="149.0" spread="38.3"/>
                    <measurement group_id="O5" value="146.5" spread="49.7"/>
                    <measurement group_id="O6" value="167.5" spread="42.3"/>
                    <measurement group_id="O7" value="212.8" spread="48.2"/>
                    <measurement group_id="O8" value="174.5" spread="34.5"/>
                    <measurement group_id="O9" value="200.5" spread="10.6"/>
                    <measurement group_id="O10" value="166.5" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="5.5"/>
                    <measurement group_id="O2" value="12.5" spread="10.6"/>
                    <measurement group_id="O3" value="5.3" spread="2.2"/>
                    <measurement group_id="O4" value="5.3" spread="6.4"/>
                    <measurement group_id="O5" value="9.5" spread="14.0"/>
                    <measurement group_id="O6" value="19.5" spread="4.0"/>
                    <measurement group_id="O7" value="8.3" spread="21.0"/>
                    <measurement group_id="O8" value="25.0" spread="12.7"/>
                    <measurement group_id="O9" value="12.5" spread="12.0"/>
                    <measurement group_id="O10" value="5.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="20.4"/>
                    <measurement group_id="O2" value="26.3" spread="27.2"/>
                    <measurement group_id="O3" value="25.3" spread="5.1"/>
                    <measurement group_id="O4" value="21.5" spread="15.5"/>
                    <measurement group_id="O5" value="28.3" spread="17.7"/>
                    <measurement group_id="O6" value="24.3" spread="16.7"/>
                    <measurement group_id="O7" value="-13.8" spread="33.7"/>
                    <measurement group_id="O8" value="6.8" spread="5.4"/>
                    <measurement group_id="O9" value="-2.5" spread="41.7"/>
                    <measurement group_id="O10" value="8.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: High Density Lipoproteins. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: High Density Lipoproteins. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="11.1"/>
                    <measurement group_id="O2" value="49.8" spread="8.4"/>
                    <measurement group_id="O3" value="45.5" spread="11.0"/>
                    <measurement group_id="O4" value="49.5" spread="8.9"/>
                    <measurement group_id="O5" value="40.0" spread="4.1"/>
                    <measurement group_id="O6" value="54.5" spread="5.5"/>
                    <measurement group_id="O7" value="51.5" spread="9.6"/>
                    <measurement group_id="O8" value="48.0" spread="13.3"/>
                    <measurement group_id="O9" value="47.0" spread="17.0"/>
                    <measurement group_id="O10" value="45.8" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="2.4"/>
                    <measurement group_id="O2" value="0.5" spread="3.1"/>
                    <measurement group_id="O3" value="1.0" spread="1.2"/>
                    <measurement group_id="O4" value="-2.5" spread="2.9"/>
                    <measurement group_id="O5" value="-1.3" spread="2.1"/>
                    <measurement group_id="O6" value="2.8" spread="2.2"/>
                    <measurement group_id="O7" value="-3.0" spread="6.0"/>
                    <measurement group_id="O8" value="10.0" spread="7.3"/>
                    <measurement group_id="O9" value="2.5" spread="7.8"/>
                    <measurement group_id="O10" value="-0.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="5.2"/>
                    <measurement group_id="O2" value="4.5" spread="5.0"/>
                    <measurement group_id="O3" value="6.3" spread="4.6"/>
                    <measurement group_id="O4" value="3.0" spread="3.6"/>
                    <measurement group_id="O5" value="7.3" spread="2.6"/>
                    <measurement group_id="O6" value="2.8" spread="5.1"/>
                    <measurement group_id="O7" value="-3.0" spread="9.9"/>
                    <measurement group_id="O8" value="8.8" spread="7.4"/>
                    <measurement group_id="O9" value="-2.0" spread="7.1"/>
                    <measurement group_id="O10" value="1.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triglycerides. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triglycerides. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" spread="19.0"/>
                    <measurement group_id="O2" value="88.5" spread="62.1"/>
                    <measurement group_id="O3" value="57.3" spread="13.0"/>
                    <measurement group_id="O4" value="84.5" spread="46.8"/>
                    <measurement group_id="O5" value="72.0" spread="9.6"/>
                    <measurement group_id="O6" value="71.0" spread="33.6"/>
                    <measurement group_id="O7" value="76.3" spread="15.7"/>
                    <measurement group_id="O8" value="117.0" spread="99.5"/>
                    <measurement group_id="O9" value="92.5" spread="57.3"/>
                    <measurement group_id="O10" value="86.3" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="7.2"/>
                    <measurement group_id="O2" value="19.0" spread="17.3"/>
                    <measurement group_id="O3" value="10.3" spread="3.0"/>
                    <measurement group_id="O4" value="31.0" spread="18.1"/>
                    <measurement group_id="O5" value="20.3" spread="16.3"/>
                    <measurement group_id="O6" value="22.5" spread="18.4"/>
                    <measurement group_id="O7" value="27.0" spread="9.5"/>
                    <measurement group_id="O8" value="-10.3" spread="46.7"/>
                    <measurement group_id="O9" value="1.5" spread="29.0"/>
                    <measurement group_id="O10" value="7.8" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="24.5"/>
                    <measurement group_id="O2" value="24.5" spread="58.6"/>
                    <measurement group_id="O3" value="30.8" spread="48.8"/>
                    <measurement group_id="O4" value="47.3" spread="75.3"/>
                    <measurement group_id="O5" value="12.5" spread="19.3"/>
                    <measurement group_id="O6" value="37.5" spread="86.5"/>
                    <measurement group_id="O7" value="37.8" spread="47.1"/>
                    <measurement group_id="O8" value="-16.5" spread="48.6"/>
                    <measurement group_id="O9" value="43.5" spread="89.8"/>
                    <measurement group_id="O10" value="-1.8" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Low Density Lipoproteins. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Low Density Lipoproteins. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.1" spread="41.9"/>
                    <measurement group_id="O2" value="83.5" spread="24.9"/>
                    <measurement group_id="O3" value="88.9" spread="32.5"/>
                    <measurement group_id="O4" value="82.5" spread="35.3"/>
                    <measurement group_id="O5" value="92.3" spread="46.4"/>
                    <measurement group_id="O6" value="98.7" spread="35.6"/>
                    <measurement group_id="O7" value="145.9" spread="45.7"/>
                    <measurement group_id="O8" value="103.1" spread="40.0"/>
                    <measurement group_id="O9" value="134.5" spread="16.3"/>
                    <measurement group_id="O10" value="103.5" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="6.9"/>
                    <measurement group_id="O2" value="8.3" spread="4.6"/>
                    <measurement group_id="O3" value="2.9" spread="3.1"/>
                    <measurement group_id="O4" value="1.4" spread="6.4"/>
                    <measurement group_id="O5" value="6.4" spread="10.3"/>
                    <measurement group_id="O6" value="12.8" spread="2.6"/>
                    <measurement group_id="O7" value="5.7" spread="16.2"/>
                    <measurement group_id="O8" value="16.7" spread="7.8"/>
                    <measurement group_id="O9" value="10.0" spread="9.9"/>
                    <measurement group_id="O10" value="4.4" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="19.7"/>
                    <measurement group_id="O2" value="17.0" spread="15.6"/>
                    <measurement group_id="O3" value="13.3" spread="10.8"/>
                    <measurement group_id="O4" value="9.6" spread="6.9"/>
                    <measurement group_id="O5" value="18.5" spread="16.4"/>
                    <measurement group_id="O6" value="14.2" spread="6.2"/>
                    <measurement group_id="O7" value="-17.9" spread="35.8"/>
                    <measurement group_id="O8" value="1.3" spread="7.7"/>
                    <measurement group_id="O9" value="-8.5" spread="30.4"/>
                    <measurement group_id="O10" value="7.2" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Bicarbonate. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Bicarbonate. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.68" spread="1.38"/>
                    <measurement group_id="O2" value="25.22" spread="0.51"/>
                    <measurement group_id="O3" value="24.78" spread="1.09"/>
                    <measurement group_id="O4" value="25.85" spread="0.53"/>
                    <measurement group_id="O5" value="24.85" spread="1.21"/>
                    <measurement group_id="O6" value="24.28" spread="0.33"/>
                    <measurement group_id="O7" value="27.05" spread="0.91"/>
                    <measurement group_id="O8" value="26.03" spread="1.80"/>
                    <measurement group_id="O9" value="24.90" spread="0.71"/>
                    <measurement group_id="O10" value="25.93" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="1.15"/>
                    <measurement group_id="O2" value="0.28" spread="1.31"/>
                    <measurement group_id="O3" value="1.05" spread="1.27"/>
                    <measurement group_id="O4" value="1.18" spread="0.90"/>
                    <measurement group_id="O5" value="0.40" spread="0.94"/>
                    <measurement group_id="O6" value="2.35" spread="0.70"/>
                    <measurement group_id="O7" value="-0.17" spread="0.94"/>
                    <measurement group_id="O8" value="0.05" spread="1.55"/>
                    <measurement group_id="O9" value="1.95" spread="0.64"/>
                    <measurement group_id="O10" value="0.05" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.38"/>
                    <measurement group_id="O2" value="0.97" spread="1.04"/>
                    <measurement group_id="O3" value="-0.58" spread="1.46"/>
                    <measurement group_id="O4" value="0.95" spread="0.88"/>
                    <measurement group_id="O5" value="-0.15" spread="0.55"/>
                    <measurement group_id="O6" value="1.65" spread="1.20"/>
                    <measurement group_id="O7" value="-2.38" spread="1.64"/>
                    <measurement group_id="O8" value="-0.20" spread="1.03"/>
                    <measurement group_id="O9" value="-0.55" spread="0.49"/>
                    <measurement group_id="O10" value="-1.23" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroid-stimulating Hormone. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroid-stimulating Hormone. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.56"/>
                    <measurement group_id="O2" value="1.26" spread="0.64"/>
                    <measurement group_id="O3" value="1.14" spread="0.36"/>
                    <measurement group_id="O4" value="1.14" spread="0.55"/>
                    <measurement group_id="O5" value="1.50" spread="0.97"/>
                    <measurement group_id="O6" value="1.55" spread="0.66"/>
                    <measurement group_id="O7" value="1.83" spread="0.78"/>
                    <measurement group_id="O8" value="1.59" spread="1.03"/>
                    <measurement group_id="O9" value="2.57" spread="2.31"/>
                    <measurement group_id="O10" value="1.93" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.09"/>
                    <measurement group_id="O2" value="0.04" spread="0.29"/>
                    <measurement group_id="O3" value="-0.12" spread="0.22"/>
                    <measurement group_id="O4" value="-0.03" spread="0.18"/>
                    <measurement group_id="O5" value="0.07" spread="0.22"/>
                    <measurement group_id="O6" value="0.46" spread="0.52"/>
                    <measurement group_id="O7" value="0.05" spread="0.35"/>
                    <measurement group_id="O8" value="-0.12" spread="0.25"/>
                    <measurement group_id="O9" value="-0.54" spread="0.65"/>
                    <measurement group_id="O10" value="-0.42" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.35"/>
                    <measurement group_id="O2" value="0.45" spread="1.02"/>
                    <measurement group_id="O3" value="0.10" spread="0.22"/>
                    <measurement group_id="O4" value="0.77" spread="0.92"/>
                    <measurement group_id="O5" value="0.32" spread="0.27"/>
                    <measurement group_id="O6" value="0.11" spread="0.58"/>
                    <measurement group_id="O7" value="0.17" spread="0.42"/>
                    <measurement group_id="O8" value="-0.06" spread="0.21"/>
                    <measurement group_id="O9" value="-0.69" spread="0.73"/>
                    <measurement group_id="O10" value="-0.10" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroxine (T4). SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroxine (T4). SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.14"/>
                    <measurement group_id="O2" value="1.22" spread="0.16"/>
                    <measurement group_id="O3" value="1.30" spread="0.14"/>
                    <measurement group_id="O4" value="1.38" spread="0.17"/>
                    <measurement group_id="O5" value="1.25" spread="0.10"/>
                    <measurement group_id="O6" value="1.08" spread="0.05"/>
                    <measurement group_id="O7" value="1.20" spread="0.14"/>
                    <measurement group_id="O8" value="1.15" spread="0.06"/>
                    <measurement group_id="O9" value="1.35" spread="0.07"/>
                    <measurement group_id="O10" value="1.22" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.08"/>
                    <measurement group_id="O2" value="0.03" spread="0.05"/>
                    <measurement group_id="O3" value="-0.08" spread="0.10"/>
                    <measurement group_id="O4" value="-0.08" spread="0.10"/>
                    <measurement group_id="O5" value="-0.05" spread="0.06"/>
                    <measurement group_id="O6" value="0.12" spread="0.05"/>
                    <measurement group_id="O7" value="0.05" spread="0.13"/>
                    <measurement group_id="O8" value="0.10" spread="0.08"/>
                    <measurement group_id="O9" value="0.05" spread="0.07"/>
                    <measurement group_id="O10" value="0.03" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.10"/>
                    <measurement group_id="O2" value="0.15" spread="0.10"/>
                    <measurement group_id="O3" value="0.02" spread="0.22"/>
                    <measurement group_id="O4" value="0.05" spread="0.06"/>
                    <measurement group_id="O5" value="0.07" spread="0.05"/>
                    <measurement group_id="O6" value="0.22" spread="0.05"/>
                    <measurement group_id="O7" value="0.05" spread="0.10"/>
                    <measurement group_id="O8" value="0.13" spread="0.05"/>
                    <measurement group_id="O9" value="-0.10" spread="0.14"/>
                    <measurement group_id="O10" value="0.10" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lactate. SAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O2">
            <title>Group II Placebo</title>
            <description>Placebo - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo + high calorie/high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lactate. SAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.98" spread="2.47"/>
                    <measurement group_id="O2" value="7.28" spread="1.86"/>
                    <measurement group_id="O3" value="8.65" spread="3.20"/>
                    <measurement group_id="O4" value="8.23" spread="2.04"/>
                    <measurement group_id="O5" value="8.10" spread="2.93"/>
                    <measurement group_id="O6" value="9.03" spread="2.08"/>
                    <measurement group_id="O7" value="7.53" spread="0.97"/>
                    <measurement group_id="O8" value="8.58" spread="2.68"/>
                    <measurement group_id="O9" value="9.85" spread="1.34"/>
                    <measurement group_id="O10" value="8.33" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="1.83"/>
                    <measurement group_id="O2" value="1.40" spread="2.82"/>
                    <measurement group_id="O3" value="-2.08" spread="2.41"/>
                    <measurement group_id="O4" value="2.10" spread="3.81"/>
                    <measurement group_id="O5" value="-0.50" spread="1.67"/>
                    <measurement group_id="O6" value="0.88" spread="3.62"/>
                    <measurement group_id="O7" value="0.78" spread="1.75"/>
                    <measurement group_id="O8" value="3.25" spread="1.54"/>
                    <measurement group_id="O9" value="-1.05" spread="0.07"/>
                    <measurement group_id="O10" value="0.40" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="4.59"/>
                    <measurement group_id="O2" value="3.80" spread="3.12"/>
                    <measurement group_id="O3" value="2.25" spread="5.84"/>
                    <measurement group_id="O4" value="3.45" spread="3.45"/>
                    <measurement group_id="O5" value="1.93" spread="6.23"/>
                    <measurement group_id="O6" value="0.70" spread="2.45"/>
                    <measurement group_id="O7" value="-0.02" spread="3.40"/>
                    <measurement group_id="O8" value="4.33" spread="3.08"/>
                    <measurement group_id="O9" value="-0.15" spread="0.64"/>
                    <measurement group_id="O10" value="1.70" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Protein. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline (pre-dose Day1), Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Protein. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="3.8"/>
                    <measurement group_id="O2" value="67.3" spread="4.6"/>
                    <measurement group_id="O3" value="63.8" spread="1.3"/>
                    <measurement group_id="O4" value="66.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.4"/>
                    <measurement group_id="O2" value="2.3" spread="1.7"/>
                    <measurement group_id="O3" value="2.5" spread="1.7"/>
                    <measurement group_id="O4" value="1.7" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="2.9"/>
                    <measurement group_id="O2" value="4.3" spread="4.3"/>
                    <measurement group_id="O3" value="6.0" spread="4.1"/>
                    <measurement group_id="O4" value="4.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="3.4"/>
                    <measurement group_id="O2" value="4.8" spread="4.1"/>
                    <measurement group_id="O3" value="4.0" spread="2.9"/>
                    <measurement group_id="O4" value="1.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alkaline Phosphatase. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alkaline Phosphatase. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" spread="16.1"/>
                    <measurement group_id="O2" value="67.3" spread="10.7"/>
                    <measurement group_id="O3" value="55.3" spread="7.3"/>
                    <measurement group_id="O4" value="52.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="6.7"/>
                    <measurement group_id="O2" value="2.0" spread="1.4"/>
                    <measurement group_id="O3" value="1.5" spread="3.9"/>
                    <measurement group_id="O4" value="1.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="9.7"/>
                    <measurement group_id="O2" value="5.0" spread="4.2"/>
                    <measurement group_id="O3" value="6.0" spread="6.4"/>
                    <measurement group_id="O4" value="3.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="13.3"/>
                    <measurement group_id="O2" value="10.8" spread="4.6"/>
                    <measurement group_id="O3" value="9.8" spread="5.2"/>
                    <measurement group_id="O4" value="3.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Aspartate Aminotransferase. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Aspartate Aminotransferase. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="3.8"/>
                    <measurement group_id="O2" value="21.5" spread="5.7"/>
                    <measurement group_id="O3" value="18.5" spread="0.6"/>
                    <measurement group_id="O4" value="23.0" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="4.2"/>
                    <measurement group_id="O2" value="-5.0" spread="1.4"/>
                    <measurement group_id="O3" value="-2.5" spread="1.3"/>
                    <measurement group_id="O4" value="-1.7" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="6.1"/>
                    <measurement group_id="O2" value="-2.8" spread="1.9"/>
                    <measurement group_id="O3" value="-0.3" spread="2.8"/>
                    <measurement group_id="O4" value="-1.5" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="3.9"/>
                    <measurement group_id="O2" value="1.3" spread="4.6"/>
                    <measurement group_id="O3" value="9.8" spread="16.3"/>
                    <measurement group_id="O4" value="2.8" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatine Kinase. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatine Kinase. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.5" spread="62.0"/>
                    <measurement group_id="O2" value="192.3" spread="149.4"/>
                    <measurement group_id="O3" value="146.5" spread="70.8"/>
                    <measurement group_id="O4" value="229.8" spread="156.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.5" spread="40.7"/>
                    <measurement group_id="O2" value="-68.8" spread="57.3"/>
                    <measurement group_id="O3" value="-58.0" spread="53.3"/>
                    <measurement group_id="O4" value="-106.5" spread="115.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.8" spread="49.4"/>
                    <measurement group_id="O2" value="-83.8" spread="91.7"/>
                    <measurement group_id="O3" value="-68.0" spread="57.7"/>
                    <measurement group_id="O4" value="-123.5" spread="144.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="23.1"/>
                    <measurement group_id="O2" value="-7.5" spread="81.2"/>
                    <measurement group_id="O3" value="150.5" spread="313.3"/>
                    <measurement group_id="O4" value="42.2" spread="153.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Gamma GT. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Gamma GT. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="7.0"/>
                    <measurement group_id="O2" value="18.3" spread="9.2"/>
                    <measurement group_id="O3" value="20.5" spread="14.5"/>
                    <measurement group_id="O4" value="21.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.0"/>
                    <measurement group_id="O2" value="0.3" spread="1.3"/>
                    <measurement group_id="O3" value="2.0" spread="2.2"/>
                    <measurement group_id="O4" value="0.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.9"/>
                    <measurement group_id="O2" value="0.3" spread="3.0"/>
                    <measurement group_id="O3" value="1.8" spread="2.8"/>
                    <measurement group_id="O4" value="0.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.3"/>
                    <measurement group_id="O2" value="-0.5" spread="3.1"/>
                    <measurement group_id="O3" value="1.8" spread="2.2"/>
                    <measurement group_id="O4" value="-0.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Bilirubin. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Bilirubin. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.47"/>
                    <measurement group_id="O2" value="0.55" spread="0.13"/>
                    <measurement group_id="O3" value="0.63" spread="0.15"/>
                    <measurement group_id="O4" value="0.65" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.22"/>
                    <measurement group_id="O2" value="0.05" spread="0.13"/>
                    <measurement group_id="O3" value="0.20" spread="0.16"/>
                    <measurement group_id="O4" value="0.13" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.26"/>
                    <measurement group_id="O2" value="0.03" spread="0.21"/>
                    <measurement group_id="O3" value="0.18" spread="0.25"/>
                    <measurement group_id="O4" value="0.08" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.32"/>
                    <measurement group_id="O2" value="-0.08" spread="0.21"/>
                    <measurement group_id="O3" value="0.08" spread="0.22"/>
                    <measurement group_id="O4" value="-0.05" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Urea. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Urea. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="3.9"/>
                    <measurement group_id="O2" value="28.0" spread="5.5"/>
                    <measurement group_id="O3" value="29.8" spread="5.1"/>
                    <measurement group_id="O4" value="30.2" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="2.2"/>
                    <measurement group_id="O2" value="2.8" spread="2.4"/>
                    <measurement group_id="O3" value="2.0" spread="2.6"/>
                    <measurement group_id="O4" value="2.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="6.9"/>
                    <measurement group_id="O2" value="-0.5" spread="3.1"/>
                    <measurement group_id="O3" value="0.5" spread="1.3"/>
                    <measurement group_id="O4" value="-1.0" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="8.4"/>
                    <measurement group_id="O2" value="-0.5" spread="6.8"/>
                    <measurement group_id="O3" value="-0.5" spread="7.1"/>
                    <measurement group_id="O4" value="-0.3" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatinine. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatinine. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.910" spread="0.042"/>
                    <measurement group_id="O2" value="0.960" spread="0.079"/>
                    <measurement group_id="O3" value="0.913" spread="0.067"/>
                    <measurement group_id="O4" value="0.897" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.095" spread="0.025"/>
                    <measurement group_id="O2" value="0.122" spread="0.033"/>
                    <measurement group_id="O3" value="0.165" spread="0.031"/>
                    <measurement group_id="O4" value="0.057" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.247"/>
                    <measurement group_id="O2" value="0.122" spread="0.069"/>
                    <measurement group_id="O3" value="0.133" spread="0.082"/>
                    <measurement group_id="O4" value="0.053" spread="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.130"/>
                    <measurement group_id="O2" value="-0.020" spread="0.024"/>
                    <measurement group_id="O3" value="0.017" spread="0.043"/>
                    <measurement group_id="O4" value="0.007" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Sodium. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Sodium. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.8" spread="1.0"/>
                    <measurement group_id="O2" value="141.3" spread="0.5"/>
                    <measurement group_id="O3" value="141.0" spread="1.4"/>
                    <measurement group_id="O4" value="142.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.6"/>
                    <measurement group_id="O2" value="-1.5" spread="0.6"/>
                    <measurement group_id="O3" value="0.8" spread="0.5"/>
                    <measurement group_id="O4" value="-1.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="0.8"/>
                    <measurement group_id="O2" value="0.8" spread="0.5"/>
                    <measurement group_id="O3" value="1.0" spread="0.8"/>
                    <measurement group_id="O4" value="-0.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.0"/>
                    <measurement group_id="O2" value="-0.3" spread="2.2"/>
                    <measurement group_id="O3" value="2.0" spread="2.2"/>
                    <measurement group_id="O4" value="0.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Potassium. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Potassium. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" spread="0.08"/>
                    <measurement group_id="O2" value="4.35" spread="0.19"/>
                    <measurement group_id="O3" value="4.40" spread="0.40"/>
                    <measurement group_id="O4" value="4.32" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.19"/>
                    <measurement group_id="O2" value="0.33" spread="0.37"/>
                    <measurement group_id="O3" value="0.10" spread="0.29"/>
                    <measurement group_id="O4" value="0.52" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.30"/>
                    <measurement group_id="O2" value="0.15" spread="0.39"/>
                    <measurement group_id="O3" value="0.25" spread="0.42"/>
                    <measurement group_id="O4" value="0.15" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.39"/>
                    <measurement group_id="O2" value="0.45" spread="0.31"/>
                    <measurement group_id="O3" value="0.25" spread="0.59"/>
                    <measurement group_id="O4" value="0.30" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Chloride. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Chloride. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.8" spread="2.2"/>
                    <measurement group_id="O2" value="101.5" spread="0.6"/>
                    <measurement group_id="O3" value="102.0" spread="1.8"/>
                    <measurement group_id="O4" value="102.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="0.6"/>
                    <measurement group_id="O2" value="-2.0" spread="1.8"/>
                    <measurement group_id="O3" value="-1.5" spread="0.6"/>
                    <measurement group_id="O4" value="-1.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="1.0"/>
                    <measurement group_id="O2" value="-2.0" spread="1.4"/>
                    <measurement group_id="O3" value="-2.8" spread="1.0"/>
                    <measurement group_id="O4" value="-2.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="0.0"/>
                    <measurement group_id="O2" value="-2.3" spread="1.9"/>
                    <measurement group_id="O3" value="-2.0" spread="0.8"/>
                    <measurement group_id="O4" value="-1.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Calcium (Corrected for Albumin). MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Calcium (Corrected for Albumin). MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.278" spread="0.117"/>
                    <measurement group_id="O2" value="2.310" spread="0.058"/>
                    <measurement group_id="O3" value="2.265" spread="0.024"/>
                    <measurement group_id="O4" value="2.323" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.105" spread="0.051"/>
                    <measurement group_id="O2" value="0.083" spread="0.067"/>
                    <measurement group_id="O3" value="0.048" spread="0.068"/>
                    <measurement group_id="O4" value="0.068" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127" spread="0.091"/>
                    <measurement group_id="O2" value="0.083" spread="0.063"/>
                    <measurement group_id="O3" value="0.100" spread="0.095"/>
                    <measurement group_id="O4" value="0.088" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.087" spread="0.088"/>
                    <measurement group_id="O2" value="0.083" spread="0.075"/>
                    <measurement group_id="O3" value="0.045" spread="0.082"/>
                    <measurement group_id="O4" value="0.055" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Uric Acid. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Uric Acid. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" spread="1.67"/>
                    <measurement group_id="O2" value="4.93" spread="0.91"/>
                    <measurement group_id="O3" value="5.40" spread="0.80"/>
                    <measurement group_id="O4" value="5.25" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.56"/>
                    <measurement group_id="O2" value="0.58" spread="0.39"/>
                    <measurement group_id="O3" value="0.75" spread="0.62"/>
                    <measurement group_id="O4" value="-0.07" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="1.14"/>
                    <measurement group_id="O2" value="-0.02" spread="0.43"/>
                    <measurement group_id="O3" value="0.15" spread="0.58"/>
                    <measurement group_id="O4" value="-0.63" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.92"/>
                    <measurement group_id="O2" value="0.55" spread="0.52"/>
                    <measurement group_id="O3" value="0.22" spread="0.81"/>
                    <measurement group_id="O4" value="-0.05" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lipase. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lipase. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="6.1"/>
                    <measurement group_id="O2" value="26.5" spread="3.3"/>
                    <measurement group_id="O3" value="32.8" spread="12.1"/>
                    <measurement group_id="O4" value="34.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="3.1"/>
                    <measurement group_id="O2" value="0.0" spread="1.8"/>
                    <measurement group_id="O3" value="26.0" spread="55.4"/>
                    <measurement group_id="O4" value="1.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="4.1"/>
                    <measurement group_id="O2" value="1.3" spread="7.4"/>
                    <measurement group_id="O3" value="50.5" spread="106.4"/>
                    <measurement group_id="O4" value="1.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="3.3"/>
                    <measurement group_id="O2" value="17.3" spread="24.4"/>
                    <measurement group_id="O3" value="-2.8" spread="7.4"/>
                    <measurement group_id="O4" value="-1.8" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alanine Aminotransferase. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alanine Aminotransferase. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="9.7"/>
                    <measurement group_id="O2" value="21.3" spread="17.4"/>
                    <measurement group_id="O3" value="20.5" spread="6.8"/>
                    <measurement group_id="O4" value="22.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="5.9"/>
                    <measurement group_id="O2" value="-0.3" spread="2.2"/>
                    <measurement group_id="O3" value="-1.3" spread="0.5"/>
                    <measurement group_id="O4" value="2.0" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="12.9"/>
                    <measurement group_id="O2" value="2.3" spread="2.6"/>
                    <measurement group_id="O3" value="0.3" spread="5.4"/>
                    <measurement group_id="O4" value="2.8" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="11.4"/>
                    <measurement group_id="O2" value="6.3" spread="8.3"/>
                    <measurement group_id="O3" value="4.8" spread="7.9"/>
                    <measurement group_id="O4" value="2.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Phosphate. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Phosphate. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.978" spread="0.094"/>
                    <measurement group_id="O2" value="1.033" spread="0.164"/>
                    <measurement group_id="O3" value="0.920" spread="0.121"/>
                    <measurement group_id="O4" value="1.000" spread="0.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.102" spread="0.033"/>
                    <measurement group_id="O2" value="0.003" spread="0.074"/>
                    <measurement group_id="O3" value="0.015" spread="0.073"/>
                    <measurement group_id="O4" value="-0.005" spread="0.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.116"/>
                    <measurement group_id="O2" value="0.000" spread="0.085"/>
                    <measurement group_id="O3" value="-0.020" spread="0.068"/>
                    <measurement group_id="O4" value="-0.002" spread="0.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.030" spread="0.131"/>
                    <measurement group_id="O2" value="-0.010" spread="0.034"/>
                    <measurement group_id="O3" value="0.053" spread="0.189"/>
                    <measurement group_id="O4" value="-0.002" spread="0.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Human Serum Albumin. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Human Serum Albumin. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="2.2"/>
                    <measurement group_id="O2" value="45.5" spread="3.1"/>
                    <measurement group_id="O3" value="42.8" spread="0.5"/>
                    <measurement group_id="O4" value="44.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.2"/>
                    <measurement group_id="O2" value="3.8" spread="1.3"/>
                    <measurement group_id="O3" value="1.3" spread="1.0"/>
                    <measurement group_id="O4" value="1.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="2.6"/>
                    <measurement group_id="O2" value="3.5" spread="3.0"/>
                    <measurement group_id="O3" value="4.0" spread="1.8"/>
                    <measurement group_id="O4" value="3.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.1"/>
                    <measurement group_id="O2" value="3.0" spread="2.4"/>
                    <measurement group_id="O3" value="3.3" spread="2.1"/>
                    <measurement group_id="O4" value="1.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Fasting Glucose. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Fasting Glucose. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" spread="5.4"/>
                    <measurement group_id="O2" value="85.5" spread="13.8"/>
                    <measurement group_id="O3" value="89.8" spread="7.5"/>
                    <measurement group_id="O4" value="87.2" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="4.5"/>
                    <measurement group_id="O2" value="2.8" spread="6.3"/>
                    <measurement group_id="O3" value="-6.8" spread="7.9"/>
                    <measurement group_id="O4" value="1.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="7.0"/>
                    <measurement group_id="O2" value="-9.5" spread="5.5"/>
                    <measurement group_id="O3" value="-7.0" spread="6.1"/>
                    <measurement group_id="O4" value="-3.5" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="1.4"/>
                    <measurement group_id="O2" value="2.0" spread="5.7"/>
                    <measurement group_id="O3" value="-10.8" spread="7.8"/>
                    <measurement group_id="O4" value="0.0" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Cholesterol. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Cholesterol. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.8" spread="33.5"/>
                    <measurement group_id="O2" value="191.0" spread="11.3"/>
                    <measurement group_id="O3" value="203.5" spread="7.4"/>
                    <measurement group_id="O4" value="177.8" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="11.5"/>
                    <measurement group_id="O2" value="8.8" spread="9.7"/>
                    <measurement group_id="O3" value="13.5" spread="4.0"/>
                    <measurement group_id="O4" value="19.7" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="25.3"/>
                    <measurement group_id="O2" value="2.5" spread="20.5"/>
                    <measurement group_id="O3" value="13.3" spread="17.7"/>
                    <measurement group_id="O4" value="24.3" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="14.2"/>
                    <measurement group_id="O2" value="8.0" spread="22.2"/>
                    <measurement group_id="O3" value="9.8" spread="17.8"/>
                    <measurement group_id="O4" value="-5.5" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Triglycerides. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Triglycerides. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.3" spread="77.7"/>
                    <measurement group_id="O2" value="83.5" spread="26.3"/>
                    <measurement group_id="O3" value="114.0" spread="74.6"/>
                    <measurement group_id="O4" value="90.2" spread="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="32.2"/>
                    <measurement group_id="O2" value="35.5" spread="32.7"/>
                    <measurement group_id="O3" value="30.5" spread="30.0"/>
                    <measurement group_id="O4" value="14.8" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="44.2"/>
                    <measurement group_id="O2" value="46.8" spread="26.9"/>
                    <measurement group_id="O3" value="69.0" spread="42.1"/>
                    <measurement group_id="O4" value="28.3" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="52.1"/>
                    <measurement group_id="O2" value="0.5" spread="33.5"/>
                    <measurement group_id="O3" value="20.3" spread="56.6"/>
                    <measurement group_id="O4" value="-8.0" spread="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Low Density Lipoproteins. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Low Density Lipoproteins. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.1" spread="32.7"/>
                    <measurement group_id="O2" value="112.9" spread="19.0"/>
                    <measurement group_id="O3" value="127.0" spread="18.1"/>
                    <measurement group_id="O4" value="93.3" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="14.5"/>
                    <measurement group_id="O2" value="4.9" spread="5.2"/>
                    <measurement group_id="O3" value="9.0" spread="7.9"/>
                    <measurement group_id="O4" value="18.8" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="32.8"/>
                    <measurement group_id="O2" value="1.4" spread="13.8"/>
                    <measurement group_id="O3" value="3.5" spread="20.0"/>
                    <measurement group_id="O4" value="25.6" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="11.0"/>
                    <measurement group_id="O2" value="6.9" spread="9.6"/>
                    <measurement group_id="O3" value="-1.5" spread="20.7"/>
                    <measurement group_id="O4" value="-1.9" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: High Density Lipoproteins. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: High Density Lipoproteins. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" spread="15.1"/>
                    <measurement group_id="O2" value="61.0" spread="20.1"/>
                    <measurement group_id="O3" value="53.5" spread="20.5"/>
                    <measurement group_id="O4" value="66.8" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="5.7"/>
                    <measurement group_id="O2" value="-3.0" spread="4.8"/>
                    <measurement group_id="O3" value="-1.5" spread="5.8"/>
                    <measurement group_id="O4" value="-2.5" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="6.1"/>
                    <measurement group_id="O2" value="-7.8" spread="8.6"/>
                    <measurement group_id="O3" value="-3.5" spread="11.2"/>
                    <measurement group_id="O4" value="-7.0" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="2.1"/>
                    <measurement group_id="O2" value="1.3" spread="9.9"/>
                    <measurement group_id="O3" value="7.5" spread="12.1"/>
                    <measurement group_id="O4" value="-2.2" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroid-stimulating Hormone. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroid-stimulating Hormone. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.78"/>
                    <measurement group_id="O2" value="1.48" spread="0.45"/>
                    <measurement group_id="O3" value="1.20" spread="0.36"/>
                    <measurement group_id="O4" value="1.58" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.33"/>
                    <measurement group_id="O2" value="0.09" spread="0.21"/>
                    <measurement group_id="O3" value="0.48" spread="0.54"/>
                    <measurement group_id="O4" value="0.25" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.35"/>
                    <measurement group_id="O2" value="0.45" spread="0.23"/>
                    <measurement group_id="O3" value="0.75" spread="0.52"/>
                    <measurement group_id="O4" value="0.85" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.50"/>
                    <measurement group_id="O2" value="-0.15" spread="0.29"/>
                    <measurement group_id="O3" value="0.05" spread="0.48"/>
                    <measurement group_id="O4" value="0.05" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Trilodothyronine (T3). MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Trilodothyronine (T3). MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="0.58"/>
                    <measurement group_id="O2" value="3.35" spread="0.26"/>
                    <measurement group_id="O3" value="3.30" spread="0.14"/>
                    <measurement group_id="O4" value="3.08" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.19"/>
                    <measurement group_id="O2" value="-0.28" spread="0.29"/>
                    <measurement group_id="O3" value="-0.15" spread="0.19"/>
                    <measurement group_id="O4" value="-0.15" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.30"/>
                    <measurement group_id="O2" value="0.10" spread="0.27"/>
                    <measurement group_id="O3" value="-0.13" spread="0.22"/>
                    <measurement group_id="O4" value="-0.05" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.26"/>
                    <measurement group_id="O2" value="-0.05" spread="0.30"/>
                    <measurement group_id="O3" value="0.18" spread="0.29"/>
                    <measurement group_id="O4" value="0.18" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroxine (T4). MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroxine (T4). MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="0.08"/>
                    <measurement group_id="O2" value="1.25" spread="0.06"/>
                    <measurement group_id="O3" value="1.20" spread="0.18"/>
                    <measurement group_id="O4" value="1.07" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.06"/>
                    <measurement group_id="O2" value="0.02" spread="0.05"/>
                    <measurement group_id="O3" value="0.05" spread="0.06"/>
                    <measurement group_id="O4" value="0.03" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.05"/>
                    <measurement group_id="O2" value="0.07" spread="0.10"/>
                    <measurement group_id="O3" value="0.23" spread="0.10"/>
                    <measurement group_id="O4" value="0.17" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.05"/>
                    <measurement group_id="O2" value="0.03" spread="0.10"/>
                    <measurement group_id="O3" value="0.12" spread="0.05"/>
                    <measurement group_id="O4" value="0.10" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Bicarbonate. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Bicarbonate. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.53" spread="0.54"/>
                    <measurement group_id="O2" value="25.53" spread="0.92"/>
                    <measurement group_id="O3" value="28.53" spread="0.59"/>
                    <measurement group_id="O4" value="27.23" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.79"/>
                    <measurement group_id="O2" value="2.20" spread="1.51"/>
                    <measurement group_id="O3" value="0.10" spread="1.55"/>
                    <measurement group_id="O4" value="0.03" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="1.62"/>
                    <measurement group_id="O2" value="1.42" spread="1.59"/>
                    <measurement group_id="O3" value="-0.55" spread="1.72"/>
                    <measurement group_id="O4" value="0.47" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="0.69"/>
                    <measurement group_id="O2" value="1.68" spread="1.27"/>
                    <measurement group_id="O3" value="-0.32" spread="1.78"/>
                    <measurement group_id="O4" value="-0.27" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lactate. MAD Group</title>
        <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
        <time_frame>Baseline, Day 3, Day 8, FU (one week after last dosing)</time_frame>
        <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lactate. MAD Group</title>
          <description>Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.</description>
          <population>The safety analysis set included all subjects who have been assigned treatment and have been administered at least once with placebo or KH176.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.63" spread="4.26"/>
                    <measurement group_id="O2" value="7.00" spread="1.82"/>
                    <measurement group_id="O3" value="7.23" spread="1.08"/>
                    <measurement group_id="O4" value="9.12" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="1.06"/>
                    <measurement group_id="O2" value="2.23" spread="4.01"/>
                    <measurement group_id="O3" value="1.18" spread="1.41"/>
                    <measurement group_id="O4" value="5.93" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="3.00"/>
                    <measurement group_id="O2" value="2.30" spread="2.08"/>
                    <measurement group_id="O3" value="1.83" spread="1.56"/>
                    <measurement group_id="O4" value="1.23" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="3.30"/>
                    <measurement group_id="O2" value="1.08" spread="1.49"/>
                    <measurement group_id="O3" value="6.63" spread="4.95"/>
                    <measurement group_id="O4" value="-0.12" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phospholipidosis</title>
        <description>Change from Day 1 to Day 7 in di-docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate (di-22:6-BMP) and normalized di-22:6-BMP (urine) - MAD</description>
        <time_frame>Day 1, Day 7</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Mad group: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Phospholipidosis</title>
          <description>Change from Day 1 to Day 7 in di-docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate (di-22:6-BMP) and normalized di-22:6-BMP (urine) - MAD</description>
          <population>Per protocol set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>di-22:6-BMP: Change from Day 1 to Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.473" spread="4.520"/>
                    <measurement group_id="O2" value="-3.465" spread="4.870"/>
                    <measurement group_id="O3" value="-2.630" spread="2.633"/>
                    <measurement group_id="O4" value="-1.592" spread="3.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized di-22:6-BMP: Change from Day 1 to Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.298" spread="0.819"/>
                    <measurement group_id="O2" value="0.060" spread="1.152"/>
                    <measurement group_id="O3" value="0.337" spread="1.120"/>
                    <measurement group_id="O4" value="1.780" spread="1.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MAD: Change From Baseline in ECG Results by Time Point: Corrected QT Interval According to Barret's Formaula (QTcB)</title>
        <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.</description>
        <time_frame>Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>MAD: Change From Baseline in ECG Results by Time Point: Corrected QT Interval According to Barret's Formaula (QTcB)</title>
          <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.</description>
          <population>Safety Analysis Set</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391.3" spread="10.8"/>
                    <measurement group_id="O2" value="381.0" spread="28.9"/>
                    <measurement group_id="O3" value="384.0" spread="11.0"/>
                    <measurement group_id="O4" value="385.2" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 2h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="10.3"/>
                    <measurement group_id="O2" value="12.3" spread="8.8"/>
                    <measurement group_id="O3" value="11.8" spread="9.7"/>
                    <measurement group_id="O4" value="0.7" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="9.8"/>
                    <measurement group_id="O2" value="0.3" spread="6.2"/>
                    <measurement group_id="O3" value="11.5" spread="19.2"/>
                    <measurement group_id="O4" value="-5.7" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (pre-dose Day 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.3" spread="7.9"/>
                    <measurement group_id="O2" value="386.5" spread="26.1"/>
                    <measurement group_id="O3" value="402.0" spread="6.6"/>
                    <measurement group_id="O4" value="378.8" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 1h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="9.1"/>
                    <measurement group_id="O2" value="-3.8" spread="7.9"/>
                    <measurement group_id="O3" value="-10.3" spread="11.1"/>
                    <measurement group_id="O4" value="-3.5" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 2h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="4.2"/>
                    <measurement group_id="O2" value="5.8" spread="15.2"/>
                    <measurement group_id="O3" value="2.5" spread="8.7"/>
                    <measurement group_id="O4" value="1.0" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 4h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="7.7"/>
                    <measurement group_id="O2" value="-3.8" spread="6.2"/>
                    <measurement group_id="O3" value="-6.5" spread="13.9"/>
                    <measurement group_id="O4" value="-0.5" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 BL at 6h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="9.8"/>
                    <measurement group_id="O2" value="12.5" spread="7.0"/>
                    <measurement group_id="O3" value="-1.8" spread="8.3"/>
                    <measurement group_id="O4" value="5.8" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 8h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="2.8"/>
                    <measurement group_id="O2" value="-4.5" spread="9.7"/>
                    <measurement group_id="O3" value="-11.5" spread="7.2"/>
                    <measurement group_id="O4" value="3.0" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 12h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="11.4"/>
                    <measurement group_id="O2" value="3.0" spread="5.0"/>
                    <measurement group_id="O3" value="-9.0" spread="8.1"/>
                    <measurement group_id="O4" value="6.7" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="9.8"/>
                    <measurement group_id="O2" value="0.3" spread="6.2"/>
                    <measurement group_id="O3" value="11.5" spread="19.2"/>
                    <measurement group_id="O4" value="-5.7" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="14.1"/>
                    <measurement group_id="O2" value="0.5" spread="9.7"/>
                    <measurement group_id="O3" value="20.5" spread="22.3"/>
                    <measurement group_id="O4" value="-8.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="11.5"/>
                    <measurement group_id="O2" value="2.0" spread="14.7"/>
                    <measurement group_id="O3" value="7.5" spread="17.1"/>
                    <measurement group_id="O4" value="-10.2" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="14.3"/>
                    <measurement group_id="O2" value="10.3" spread="4.3"/>
                    <measurement group_id="O3" value="14.0" spread="14.2"/>
                    <measurement group_id="O4" value="-8.5" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="9.9"/>
                    <measurement group_id="O2" value="-2.3" spread="6.7"/>
                    <measurement group_id="O3" value="13.5" spread="13.8"/>
                    <measurement group_id="O4" value="-10.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="6.5"/>
                    <measurement group_id="O2" value="5.5" spread="9.6"/>
                    <measurement group_id="O3" value="18.0" spread="9.2"/>
                    <measurement group_id="O4" value="-11.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="9.7"/>
                    <measurement group_id="O2" value="11.0" spread="3.2"/>
                    <measurement group_id="O3" value="10.5" spread="24.4"/>
                    <measurement group_id="O4" value="3.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MAD: Change From Baseline in ECG Results by Time Point: P Wave-Q Wave Interval (PQ Interval)</title>
        <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the PQ interval the average of the 3 recordings will be taken as baseline.</description>
        <time_frame>Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>MAD group:Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>MAD: Change From Baseline in ECG Results by Time Point: P Wave-Q Wave Interval (PQ Interval)</title>
          <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the PQ interval the average of the 3 recordings will be taken as baseline.</description>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.8" spread="33.4"/>
                    <measurement group_id="O2" value="160.5" spread="18.5"/>
                    <measurement group_id="O3" value="162.0" spread="7.0"/>
                    <measurement group_id="O4" value="171.8" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 2h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.8"/>
                    <measurement group_id="O2" value="-1.5" spread="3.0"/>
                    <measurement group_id="O3" value="6.0" spread="5.0"/>
                    <measurement group_id="O4" value="6.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="6.1"/>
                    <measurement group_id="O2" value="-0.5" spread="1.9"/>
                    <measurement group_id="O3" value="2.0" spread="6.6"/>
                    <measurement group_id="O4" value="-6.5" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (pre-dose Day 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.5" spread="33.4"/>
                    <measurement group_id="O2" value="164.0" spread="22.9"/>
                    <measurement group_id="O3" value="167.5" spread="5.3"/>
                    <measurement group_id="O4" value="178.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 1h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="4.8"/>
                    <measurement group_id="O2" value="5.5" spread="30"/>
                    <measurement group_id="O3" value="6.5" spread="2.5"/>
                    <measurement group_id="O4" value="-1.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 2h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="5.7"/>
                    <measurement group_id="O2" value="-1.5" spread="3.4"/>
                    <measurement group_id="O3" value="4.0" spread="4.3"/>
                    <measurement group_id="O4" value="-14.7" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 4h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="9.0"/>
                    <measurement group_id="O2" value="-1.0" spread="3.8"/>
                    <measurement group_id="O3" value="0.0" spread="1.6"/>
                    <measurement group_id="O4" value="-14.3" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 BL at 6h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" spread="4.8"/>
                    <measurement group_id="O2" value="-3.5" spread="8.2"/>
                    <measurement group_id="O3" value="-4.5" spread="2.5"/>
                    <measurement group_id="O4" value="-6.7" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 8h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="5.9"/>
                    <measurement group_id="O2" value="0.0" spread="7.3"/>
                    <measurement group_id="O3" value="-5.0" spread="2.6"/>
                    <measurement group_id="O4" value="-11.3" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 12h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0" spread="23.6"/>
                    <measurement group_id="O2" value="-1.5" spread="5.7"/>
                    <measurement group_id="O3" value="-4.5" spread="4.1"/>
                    <measurement group_id="O4" value="-4.0" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="6.1"/>
                    <measurement group_id="O2" value="-0.5" spread="1.9"/>
                    <measurement group_id="O3" value="2.0" spread="6.6"/>
                    <measurement group_id="O4" value="-6.5" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="5.4"/>
                    <measurement group_id="O2" value="4.5" spread="2.5"/>
                    <measurement group_id="O3" value="0.0" spread="6.8"/>
                    <measurement group_id="O4" value="-6.8" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="3.3"/>
                    <measurement group_id="O2" value="9.5" spread="1.0"/>
                    <measurement group_id="O3" value="7.5" spread="6.8"/>
                    <measurement group_id="O4" value="-3.8" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="7.4"/>
                    <measurement group_id="O2" value="4.0" spread="6.2"/>
                    <measurement group_id="O3" value="8.5" spread="10.1"/>
                    <measurement group_id="O4" value="-2.2" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="9.5"/>
                    <measurement group_id="O2" value="3.0" spread="4.3"/>
                    <measurement group_id="O3" value="6.0" spread="3.5"/>
                    <measurement group_id="O4" value="5.2" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="6.8"/>
                    <measurement group_id="O2" value="3.5" spread="5.7"/>
                    <measurement group_id="O3" value="5.5" spread="5.7"/>
                    <measurement group_id="O4" value="6.5" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="12.0"/>
                    <measurement group_id="O2" value="-2.5" spread="3.4"/>
                    <measurement group_id="O3" value="-3.5" spread="6.4"/>
                    <measurement group_id="O4" value="0.5" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MAD: Change From Baseline in ECG Results by Time Point: the Interval That Denotes Depolarization of the Ventricles, Between the Beginning of the Q Wave and the End of the S Wave (QRS Interval)</title>
        <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.</description>
        <time_frame>Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>MAD: Change From Baseline in ECG Results by Time Point: the Interval That Denotes Depolarization of the Ventricles, Between the Beginning of the Q Wave and the End of the S Wave (QRS Interval)</title>
          <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.</description>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" spread="6.9"/>
                    <measurement group_id="O2" value="92.5" spread="6.1"/>
                    <measurement group_id="O3" value="85.5" spread="8.3"/>
                    <measurement group_id="O4" value="98.5" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 2h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.0"/>
                    <measurement group_id="O2" value="2.0" spread="1.4"/>
                    <measurement group_id="O3" value="6.0" spread="2.9"/>
                    <measurement group_id="O4" value="-0.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.1"/>
                    <measurement group_id="O2" value="2.5" spread="2.4"/>
                    <measurement group_id="O3" value="3.5" spread="2.6"/>
                    <measurement group_id="O4" value="-0.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (pre-dose Day 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" spread="7.2"/>
                    <measurement group_id="O2" value="97.0" spread="5.3"/>
                    <measurement group_id="O3" value="87.5" spread="7.2"/>
                    <measurement group_id="O4" value="98.7" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 at 1h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.0"/>
                    <measurement group_id="O2" value="0.0" spread="2.8"/>
                    <measurement group_id="O3" value="5.0" spread="2.0"/>
                    <measurement group_id="O4" value="-0.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 at 2h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.9"/>
                    <measurement group_id="O2" value="1.0" spread="1.2"/>
                    <measurement group_id="O3" value="5.5" spread="1.9"/>
                    <measurement group_id="O4" value="0.7" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 at 4h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.8"/>
                    <measurement group_id="O2" value="-0.5" spread="1.0"/>
                    <measurement group_id="O3" value="2.5" spread="2.5"/>
                    <measurement group_id="O4" value="0.7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 BL at 6h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.9"/>
                    <measurement group_id="O2" value="-2.5" spread="2.5"/>
                    <measurement group_id="O3" value="3.0" spread="2.0"/>
                    <measurement group_id="O4" value="0.7" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 at 8h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="1.9"/>
                    <measurement group_id="O2" value="-0.5" spread="1.9"/>
                    <measurement group_id="O3" value="2.0" spread="1.6"/>
                    <measurement group_id="O4" value="0.7" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL Day 7 at 12h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="3.0"/>
                    <measurement group_id="O2" value="-2.0" spread="1.6"/>
                    <measurement group_id="O3" value="2.0" spread="0.0"/>
                    <measurement group_id="O4" value="-2.0" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.1"/>
                    <measurement group_id="O2" value="2.5" spread="2.4"/>
                    <measurement group_id="O3" value="3.5" spread="2.6"/>
                    <measurement group_id="O4" value="-0.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.1"/>
                    <measurement group_id="O2" value="2.5" spread="1.3"/>
                    <measurement group_id="O3" value="2.0" spread="3.7"/>
                    <measurement group_id="O4" value="-0.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.5"/>
                    <measurement group_id="O2" value="5.0" spread="3.4"/>
                    <measurement group_id="O3" value="3.5" spread="1.7"/>
                    <measurement group_id="O4" value="-0.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.5"/>
                    <measurement group_id="O2" value="2.5" spread="0.6"/>
                    <measurement group_id="O3" value="2.5" spread="1.7"/>
                    <measurement group_id="O4" value="-0.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.3"/>
                    <measurement group_id="O2" value="2.0" spread="2.4"/>
                    <measurement group_id="O3" value="1.0" spread="2.2"/>
                    <measurement group_id="O4" value="-1.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.5"/>
                    <measurement group_id="O2" value="4.5" spread="1.3"/>
                    <measurement group_id="O3" value="2.0" spread="1.4"/>
                    <measurement group_id="O4" value="0.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.6"/>
                    <measurement group_id="O2" value="0.5" spread="1.7"/>
                    <measurement group_id="O3" value="-2.5" spread="2.4"/>
                    <measurement group_id="O4" value="-1.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MAD: Change From Baseline in ECG Results by Time Point: QT Interval</title>
        <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.</description>
        <time_frame>Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group III</title>
            <description>MAD group III:100mg BID</description>
          </group>
          <group group_id="O2">
            <title>MAD Group IV</title>
            <description>MAD group IV: 200mg BID</description>
          </group>
          <group group_id="O3">
            <title>MAD Group V</title>
            <description>MAD group V: 400mg BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>MAD: Change From Baseline in ECG Results by Time Point: QT Interval</title>
          <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.</description>
          <population>Per protocol set</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.5" spread="41.8"/>
                    <measurement group_id="O2" value="391.5" spread="8.5"/>
                    <measurement group_id="O3" value="399.0" spread="11.2"/>
                    <measurement group_id="O4" value="410.2" spread="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 2h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="10.5"/>
                    <measurement group_id="O2" value="-7.5" spread="16.0"/>
                    <measurement group_id="O3" value="-4.0" spread="3.7"/>
                    <measurement group_id="O4" value="4.2" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="11.9"/>
                    <measurement group_id="O2" value="1.0" spread="8.8"/>
                    <measurement group_id="O3" value="-14.5" spread="4.8"/>
                    <measurement group_id="O4" value="-4.2" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (pre-dose Day 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393.0" spread="42.6"/>
                    <measurement group_id="O2" value="388.5" spread="20.6"/>
                    <measurement group_id="O3" value="402.0" spread="18.8"/>
                    <measurement group_id="O4" value="406.0" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 1h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="12.4"/>
                    <measurement group_id="O2" value="-1.0" spread="7.4"/>
                    <measurement group_id="O3" value="0.0" spread="9.1"/>
                    <measurement group_id="O4" value="1.0" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 2h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="6.5"/>
                    <measurement group_id="O2" value="-10.5" spread="15.4"/>
                    <measurement group_id="O3" value="-7.5" spread="10.0"/>
                    <measurement group_id="O4" value="-2.3" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 4h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="1.2"/>
                    <measurement group_id="O2" value="-2.0" spread="7.1"/>
                    <measurement group_id="O3" value="-4.0" spread="11.9"/>
                    <measurement group_id="O4" value="10.7" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 BL at 6h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.5" spread="14.2"/>
                    <measurement group_id="O2" value="-17.0" spread="15.2"/>
                    <measurement group_id="O3" value="-16.5" spread="10.6"/>
                    <measurement group_id="O4" value="-14.3" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 8h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.5" spread="13.7"/>
                    <measurement group_id="O2" value="-1.0" spread="12.7"/>
                    <measurement group_id="O3" value="-11.0" spread="11.9"/>
                    <measurement group_id="O4" value="-3.0" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dose Day 7 at 12h - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0" spread="14.1"/>
                    <measurement group_id="O2" value="-20.0" spread="6.3"/>
                    <measurement group_id="O3" value="-11.5" spread="9.6"/>
                    <measurement group_id="O4" value="-8.7" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="11.9"/>
                    <measurement group_id="O2" value="1.0" spread="8.8"/>
                    <measurement group_id="O3" value="-14.5" spread="4.8"/>
                    <measurement group_id="O4" value="-4.2" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="20.0"/>
                    <measurement group_id="O2" value="7.5" spread="6.6"/>
                    <measurement group_id="O3" value="-10.0" spread="9.6"/>
                    <measurement group_id="O4" value="-6.2" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="26.1"/>
                    <measurement group_id="O2" value="-3.5" spread="13.4"/>
                    <measurement group_id="O3" value="6.0" spread="4.5"/>
                    <measurement group_id="O4" value="-0.2" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="24.9"/>
                    <measurement group_id="O2" value="-13.0" spread="11.9"/>
                    <measurement group_id="O3" value="3.0" spread="9.4"/>
                    <measurement group_id="O4" value="1.2" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" spread="23.5"/>
                    <measurement group_id="O2" value="-0.5" spread="12.2"/>
                    <measurement group_id="O3" value="-4.5" spread="10.1"/>
                    <measurement group_id="O4" value="-3.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at pre-dose Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.5" spread="32.3"/>
                    <measurement group_id="O2" value="-3.0" spread="14.8"/>
                    <measurement group_id="O3" value="3.0" spread="9.4"/>
                    <measurement group_id="O4" value="-4.2" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.0" spread="13.2"/>
                    <measurement group_id="O2" value="-10.5" spread="14.6"/>
                    <measurement group_id="O3" value="-23.0" spread="14.3"/>
                    <measurement group_id="O4" value="13.2" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SAD: Change From Baseline in ECG Results by Time Point: PQ Interval</title>
        <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
        <time_frame>Pre-dose, Day 1, Day 7</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I Placebo</title>
            <description>SAD group I - Placebo</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II Placebo</title>
            <description>SAD group II - Placebo</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo - single dose + Food</description>
          </group>
          <group group_id="O10">
            <title>Group II 100mg + Food</title>
            <description>100mg KH176 - single dose + Food</description>
          </group>
        </group_list>
        <measure>
          <title>SAD: Change From Baseline in ECG Results by Time Point: PQ Interval</title>
          <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
          <population>Per protocol set</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.5" spread="28.9"/>
                    <measurement group_id="O2" value="165.0" spread="21.6"/>
                    <measurement group_id="O3" value="154.5" spread="39.2"/>
                    <measurement group_id="O4" value="159.8" spread="23.0"/>
                    <measurement group_id="O5" value="155.0" spread="24.4"/>
                    <measurement group_id="O6" value="176.5" spread="21.4"/>
                    <measurement group_id="O7" value="171.8" spread="15.9"/>
                    <measurement group_id="O8" value="176.0" spread="17.7"/>
                    <measurement group_id="O9" value="177.0" spread="26.9"/>
                    <measurement group_id="O10" value="147.5" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 1h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="4.0"/>
                    <measurement group_id="O2" value="3.3" spread="7.4"/>
                    <measurement group_id="O3" value="-0.5" spread="1.9"/>
                    <measurement group_id="O4" value="-1.3" spread="5.7"/>
                    <measurement group_id="O5" value="-4.0" spread="3.7"/>
                    <measurement group_id="O6" value="4.0" spread="2.8"/>
                    <measurement group_id="O7" value="8.8" spread="3.0"/>
                    <measurement group_id="O8" value="20.5" spread="7.5"/>
                    <measurement group_id="O9" value="-9.0" spread="9.9"/>
                    <measurement group_id="O10" value="-3.5" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 2h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="3.9"/>
                    <measurement group_id="O2" value="-0.7" spread="3.7"/>
                    <measurement group_id="O3" value="-3.0" spread="3.7"/>
                    <measurement group_id="O4" value="1.3" spread="3.8"/>
                    <measurement group_id="O5" value="-3.0" spread="3.8"/>
                    <measurement group_id="O6" value="4.5" spread="5.7"/>
                    <measurement group_id="O7" value="8.3" spread="11.8"/>
                    <measurement group_id="O8" value="16.0" spread="5.9"/>
                    <measurement group_id="O9" value="-11.0" spread="9.9"/>
                    <measurement group_id="O10" value="-1.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 4h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="8.8"/>
                    <measurement group_id="O2" value="-2.3" spread="0.8"/>
                    <measurement group_id="O3" value="-2.0" spread="2.6"/>
                    <measurement group_id="O4" value="4.8" spread="4.4"/>
                    <measurement group_id="O5" value="-3.5" spread="5.3"/>
                    <measurement group_id="O6" value="0.0" spread="4.0"/>
                    <measurement group_id="O7" value="3.3" spread="5.7"/>
                    <measurement group_id="O8" value="10.0" spread="6.3"/>
                    <measurement group_id="O9" value="-5.0" spread="7.1"/>
                    <measurement group_id="O10" value="-1.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 6h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="3.6"/>
                    <measurement group_id="O2" value="-2.7" spread="3.3"/>
                    <measurement group_id="O3" value="-2.0" spread="2.6"/>
                    <measurement group_id="O4" value="0.8" spread="7.2"/>
                    <measurement group_id="O5" value="-7.5" spread="5.3"/>
                    <measurement group_id="O6" value="-5.5" spread="8.5"/>
                    <measurement group_id="O7" value="-3.3" spread="8.8"/>
                    <measurement group_id="O8" value="9.0" spread="6.0"/>
                    <measurement group_id="O9" value="-11.0" spread="12.7"/>
                    <measurement group_id="O10" value="-1.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 8h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="3.6"/>
                    <measurement group_id="O2" value="1.0" spread="6.2"/>
                    <measurement group_id="O3" value="-6.5" spread="5.5"/>
                    <measurement group_id="O4" value="-1.3" spread="7.4"/>
                    <measurement group_id="O5" value="-8.0" spread="4.3"/>
                    <measurement group_id="O6" value="-8.0" spread="8.6"/>
                    <measurement group_id="O7" value="-5.3" spread="7.8"/>
                    <measurement group_id="O8" value="1.0" spread="10.4"/>
                    <measurement group_id="O9" value="-6.0" spread="2.8"/>
                    <measurement group_id="O10" value="-4.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BLat 12h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="4.7"/>
                    <measurement group_id="O2" value="-3.7" spread="8.3"/>
                    <measurement group_id="O3" value="-4.0" spread="4.8"/>
                    <measurement group_id="O4" value="-1.8" spread="4.9"/>
                    <measurement group_id="O5" value="-6.5" spread="4.4"/>
                    <measurement group_id="O6" value="-9.5" spread="10.6"/>
                    <measurement group_id="O7" value="-4.3" spread="5.7"/>
                    <measurement group_id="O8" value="0.5" spread="7.7"/>
                    <measurement group_id="O9" value="-9.0" spread="12.7"/>
                    <measurement group_id="O10" value="-1.5" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="3.3"/>
                    <measurement group_id="O2" value="-3.7" spread="8.5"/>
                    <measurement group_id="O3" value="-4.5" spread="8.4"/>
                    <measurement group_id="O4" value="-4.3" spread="2.6"/>
                    <measurement group_id="O5" value="-7.0" spread="3.5"/>
                    <measurement group_id="O6" value="-6.5" spread="3.0"/>
                    <measurement group_id="O7" value="-4.3" spread="4.9"/>
                    <measurement group_id="O8" value="-5.5" spread="8.9"/>
                    <measurement group_id="O9" value="0.0" spread="0.0"/>
                    <measurement group_id="O10" value="-2.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="4.9"/>
                    <measurement group_id="O2" value="-1.3" spread="7.4"/>
                    <measurement group_id="O3" value="-5.0" spread="4.3"/>
                    <measurement group_id="O4" value="-7.3" spread="2.2"/>
                    <measurement group_id="O5" value="-11.0" spread="5.3"/>
                    <measurement group_id="O6" value="-3.0" spread="9.3"/>
                    <measurement group_id="O7" value="-9.8" spread="4.9"/>
                    <measurement group_id="O8" value="-7.0" spread="2.6"/>
                    <measurement group_id="O9" value="-16.0" spread="14.1"/>
                    <measurement group_id="O10" value="-3.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SAD: Change From Baseline in ECG Results by Time Point: QRS Interval</title>
        <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
        <time_frame>Pre-dose, Day 1, Day 7</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I Placebo</title>
            <description>SAD group I - Placebo</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II Placebo</title>
            <description>SAD group II - Placebo</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo - single dose + Food</description>
          </group>
          <group group_id="O10">
            <title>Group II 100mg + Food</title>
            <description>100mg KH176 - single dose + Food</description>
          </group>
        </group_list>
        <measure>
          <title>SAD: Change From Baseline in ECG Results by Time Point: QRS Interval</title>
          <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
          <population>Per protocol set</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.0" spread="8.3"/>
                    <measurement group_id="O2" value="97.0" spread="9.6"/>
                    <measurement group_id="O3" value="99.3" spread="3.3"/>
                    <measurement group_id="O4" value="97.8" spread="7.6"/>
                    <measurement group_id="O5" value="106.5" spread="10.2"/>
                    <measurement group_id="O6" value="92.5" spread="13.9"/>
                    <measurement group_id="O7" value="104.5" spread="10.6"/>
                    <measurement group_id="O8" value="94.0" spread="8.8"/>
                    <measurement group_id="O9" value="95.0" spread="7.1"/>
                    <measurement group_id="O10" value="105.5" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 1h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.0"/>
                    <measurement group_id="O2" value="1.0" spread="5.2"/>
                    <measurement group_id="O3" value="-1.3" spread="0.5"/>
                    <measurement group_id="O4" value="0.3" spread="2.2"/>
                    <measurement group_id="O5" value="0.0" spread="2.8"/>
                    <measurement group_id="O6" value="3.5" spread="3.4"/>
                    <measurement group_id="O7" value="1.5" spread="6.4"/>
                    <measurement group_id="O8" value="26.0" spread="6.9"/>
                    <measurement group_id="O9" value="1.0" spread="1.4"/>
                    <measurement group_id="O10" value="0.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 2h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="3.0"/>
                    <measurement group_id="O2" value="0.7" spread="3.2"/>
                    <measurement group_id="O3" value="-1.3" spread="1.3"/>
                    <measurement group_id="O4" value="-0.3" spread="1.0"/>
                    <measurement group_id="O5" value="-2.5" spread="1.0"/>
                    <measurement group_id="O6" value="3.0" spread="2.6"/>
                    <measurement group_id="O7" value="2.5" spread="7.2"/>
                    <measurement group_id="O8" value="20.5" spread="7.7"/>
                    <measurement group_id="O9" value="0.0" spread="0.0"/>
                    <measurement group_id="O10" value="-2.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 4h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="3.0"/>
                    <measurement group_id="O2" value="-0.7" spread="2.2"/>
                    <measurement group_id="O3" value="-1.3" spread="1.7"/>
                    <measurement group_id="O4" value="-0.8" spread="0.5"/>
                    <measurement group_id="O5" value="-2.0" spread="0.0"/>
                    <measurement group_id="O6" value="2.0" spread="2.8"/>
                    <measurement group_id="O7" value="2.5" spread="3.0"/>
                    <measurement group_id="O8" value="17.0" spread="6.0"/>
                    <measurement group_id="O9" value="0.0" spread="2.8"/>
                    <measurement group_id="O10" value="-3.5" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 6h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.8"/>
                    <measurement group_id="O2" value="0.3" spread="1.6"/>
                    <measurement group_id="O3" value="0.8" spread="2.6"/>
                    <measurement group_id="O4" value="-0.3" spread="2.8"/>
                    <measurement group_id="O5" value="-1.5" spread="1.0"/>
                    <measurement group_id="O6" value="3.5" spread="2.5"/>
                    <measurement group_id="O7" value="1.5" spread="2.5"/>
                    <measurement group_id="O8" value="14.5" spread="5.3"/>
                    <measurement group_id="O9" value="1.0" spread="1.4"/>
                    <measurement group_id="O10" value="-1.5" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 8h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.8"/>
                    <measurement group_id="O2" value="-1.0" spread="1.3"/>
                    <measurement group_id="O3" value="1.3" spread="3.3"/>
                    <measurement group_id="O4" value="-0.8" spread="2.1"/>
                    <measurement group_id="O5" value="-2.0" spread="1.6"/>
                    <measurement group_id="O6" value="2.5" spread="1.9"/>
                    <measurement group_id="O7" value="0.0" spread="6.7"/>
                    <measurement group_id="O8" value="13.0" spread="4.8"/>
                    <measurement group_id="O9" value="0.0" spread="0.0"/>
                    <measurement group_id="O10" value="-0.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 12h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="3.6"/>
                    <measurement group_id="O2" value="-1.7" spread="1.0"/>
                    <measurement group_id="O3" value="0.3" spread="2.5"/>
                    <measurement group_id="O4" value="-0.3" spread="2.5"/>
                    <measurement group_id="O5" value="-1.5" spread="2.5"/>
                    <measurement group_id="O6" value="1.0" spread="2.6"/>
                    <measurement group_id="O7" value="2.5" spread="3.0"/>
                    <measurement group_id="O8" value="7.0" spread="2.0"/>
                    <measurement group_id="O9" value="0.0" spread="0.0"/>
                    <measurement group_id="O10" value="-2.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="5.3"/>
                    <measurement group_id="O2" value="-1.7" spread="3.4"/>
                    <measurement group_id="O3" value="-1.3" spread="0.5"/>
                    <measurement group_id="O4" value="-2.3" spread="2.2"/>
                    <measurement group_id="O5" value="-1.5" spread="1.9"/>
                    <measurement group_id="O6" value="1.5" spread="4.4"/>
                    <measurement group_id="O7" value="0.0" spread="1.6"/>
                    <measurement group_id="O8" value="4.0" spread="0.0"/>
                    <measurement group_id="O9" value="-3.0" spread="4.2"/>
                    <measurement group_id="O10" value="-1.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="6.2"/>
                    <measurement group_id="O2" value="-0.7" spread="4.4"/>
                    <measurement group_id="O3" value="-1.3" spread="3.5"/>
                    <measurement group_id="O4" value="0.8" spread="6.4"/>
                    <measurement group_id="O5" value="-2.5" spread="4.1"/>
                    <measurement group_id="O6" value="0.0" spread="3.3"/>
                    <measurement group_id="O7" value="-3.0" spread="5.3"/>
                    <measurement group_id="O8" value="-0.5" spread="2.5"/>
                    <measurement group_id="O9" value="-1.0" spread="4.2"/>
                    <measurement group_id="O10" value="-1.5" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SAD: Change From Baseline in ECG Results by Time Point: QT Interval</title>
        <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
        <time_frame>Pre-dose, Day 1, Day 7</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I Placebo</title>
            <description>SAD group I - Placebo</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II Placebo</title>
            <description>SAD group II - Placebo</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo - single dose + Food</description>
          </group>
          <group group_id="O10">
            <title>Group II 100mg + Food</title>
            <description>100mg KH176 - single dose + Food</description>
          </group>
        </group_list>
        <measure>
          <title>SAD: Change From Baseline in ECG Results by Time Point: QT Interval</title>
          <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
          <population>Per protocol set</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400.0" spread="18.6"/>
                    <measurement group_id="O2" value="415.0" spread="23.5"/>
                    <measurement group_id="O3" value="393.3" spread="15.4"/>
                    <measurement group_id="O4" value="416.0" spread="15.6"/>
                    <measurement group_id="O5" value="404.0" spread="11.4"/>
                    <measurement group_id="O6" value="409.0" spread="28.2"/>
                    <measurement group_id="O7" value="396.3" spread="15.9"/>
                    <measurement group_id="O8" value="398.3" spread="17.3"/>
                    <measurement group_id="O9" value="373.0" spread="7.1"/>
                    <measurement group_id="O10" value="396.0" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 1h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="12.7"/>
                    <measurement group_id="O2" value="-4.3" spread="13.6"/>
                    <measurement group_id="O3" value="2.3" spread="6.4"/>
                    <measurement group_id="O4" value="-8.5" spread="9.5"/>
                    <measurement group_id="O5" value="10.5" spread="5.3"/>
                    <measurement group_id="O6" value="-3.0" spread="7.4"/>
                    <measurement group_id="O7" value="-5.8" spread="17.6"/>
                    <measurement group_id="O8" value="8.8" spread="22.7"/>
                    <measurement group_id="O9" value="-11.0" spread="1.4"/>
                    <measurement group_id="O10" value="-15.5" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 2h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="8.5"/>
                    <measurement group_id="O2" value="-7.3" spread="16.2"/>
                    <measurement group_id="O3" value="4.8" spread="21.4"/>
                    <measurement group_id="O4" value="0.5" spread="9.7"/>
                    <measurement group_id="O5" value="9.0" spread="10.9"/>
                    <measurement group_id="O6" value="-2.5" spread="6.6"/>
                    <measurement group_id="O7" value="3.3" spread="17.1"/>
                    <measurement group_id="O8" value="4.8" spread="21.9"/>
                    <measurement group_id="O9" value="-2.0" spread="5.7"/>
                    <measurement group_id="O10" value="16.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 4h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="7.5"/>
                    <measurement group_id="O2" value="-3.7" spread="16.9"/>
                    <measurement group_id="O3" value="3.3" spread="9.0"/>
                    <measurement group_id="O4" value="6.0" spread="7.1"/>
                    <measurement group_id="O5" value="7.0" spread="12.9"/>
                    <measurement group_id="O6" value="-2.0" spread="11.4"/>
                    <measurement group_id="O7" value="-3.8" spread="16.7"/>
                    <measurement group_id="O8" value="1.8" spread="14.6"/>
                    <measurement group_id="O9" value="7.0" spread="4.2"/>
                    <measurement group_id="O10" value="-4.0" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 6h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="8.8"/>
                    <measurement group_id="O2" value="-16.0" spread="14.8"/>
                    <measurement group_id="O3" value="-9.8" spread="8.5"/>
                    <measurement group_id="O4" value="-19.5" spread="7.4"/>
                    <measurement group_id="O5" value="-3.5" spread="13.2"/>
                    <measurement group_id="O6" value="-11.0" spread="6.2"/>
                    <measurement group_id="O7" value="-19.3" spread="9.2"/>
                    <measurement group_id="O8" value="-4.8" spread="16.3"/>
                    <measurement group_id="O9" value="-14.0" spread="5.7"/>
                    <measurement group_id="O10" value="-13.0" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 8h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="4.4"/>
                    <measurement group_id="O2" value="-24.0" spread="9.9"/>
                    <measurement group_id="O3" value="-6.8" spread="9.1"/>
                    <measurement group_id="O4" value="-18.5" spread="4.0"/>
                    <measurement group_id="O5" value="-4.0" spread="16.6"/>
                    <measurement group_id="O6" value="-16.0" spread="9.8"/>
                    <measurement group_id="O7" value="-14.8" spread="9.3"/>
                    <measurement group_id="O8" value="-5.3" spread="7.1"/>
                    <measurement group_id="O9" value="-17.0" spread="15.6"/>
                    <measurement group_id="O10" value="-9.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 12h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="3.3"/>
                    <measurement group_id="O2" value="-24.3" spread="16.3"/>
                    <measurement group_id="O3" value="-2.8" spread="9.0"/>
                    <measurement group_id="O4" value="-15.5" spread="11.2"/>
                    <measurement group_id="O5" value="-6.5" spread="13.0"/>
                    <measurement group_id="O6" value="-22.5" spread="6.8"/>
                    <measurement group_id="O7" value="-12.3" spread="7.5"/>
                    <measurement group_id="O8" value="-13.3" spread="15.9"/>
                    <measurement group_id="O9" value="-18.0" spread="17.0"/>
                    <measurement group_id="O10" value="-10.0" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="6.1"/>
                    <measurement group_id="O2" value="-23.0" spread="13.5"/>
                    <measurement group_id="O3" value="-11.8" spread="3.0"/>
                    <measurement group_id="O4" value="-15.5" spread="16.5"/>
                    <measurement group_id="O5" value="-4.5" spread="8.2"/>
                    <measurement group_id="O6" value="-17.0" spread="14.7"/>
                    <measurement group_id="O7" value="-10.3" spread="13.3"/>
                    <measurement group_id="O8" value="2.3" spread="4.9"/>
                    <measurement group_id="O9" value="-3.0" spread="18.4"/>
                    <measurement group_id="O10" value="-7.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.0" spread="4.3"/>
                    <measurement group_id="O2" value="-18.3" spread="11.4"/>
                    <measurement group_id="O3" value="-13.8" spread="6.7"/>
                    <measurement group_id="O4" value="-12.5" spread="9.8"/>
                    <measurement group_id="O5" value="-9.0" spread="5.0"/>
                    <measurement group_id="O6" value="-12.0" spread="13.4"/>
                    <measurement group_id="O7" value="-8.3" spread="12.4"/>
                    <measurement group_id="O8" value="-7.8" spread="10.1"/>
                    <measurement group_id="O9" value="-2.0" spread="25.5"/>
                    <measurement group_id="O10" value="-1.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SAD: Change From Baseline in ECG Results by Time Point: QTcB Interval</title>
        <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
        <time_frame>Pre-dose, Day1, Day 7</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I Placebo</title>
            <description>SAD group I Placebo</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II Placebo</title>
            <description>SAD group II Placebo</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O8">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O9">
            <title>Group I Placebo + Food</title>
            <description>Placebo - single dose + Food</description>
          </group>
          <group group_id="O10">
            <title>Group II 100mg + Food</title>
            <description>100mg KH176 - single dose + Food</description>
          </group>
        </group_list>
        <measure>
          <title>SAD: Change From Baseline in ECG Results by Time Point: QTcB Interval</title>
          <description>The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.</description>
          <population>Per protocol set</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-dose Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.3" spread="21.0"/>
                    <measurement group_id="O2" value="385.5" spread="9.8"/>
                    <measurement group_id="O3" value="382.0" spread="21.4"/>
                    <measurement group_id="O4" value="390.5" spread="8.9"/>
                    <measurement group_id="O5" value="383.8" spread="24.8"/>
                    <measurement group_id="O6" value="386.3" spread="8.0"/>
                    <measurement group_id="O7" value="382.0" spread="10.9"/>
                    <measurement group_id="O8" value="378.5" spread="19.1"/>
                    <measurement group_id="O9" value="367.5" spread="24.7"/>
                    <measurement group_id="O10" value="382.3" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 1h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="7.7"/>
                    <measurement group_id="O2" value="-0.7" spread="10.1"/>
                    <measurement group_id="O3" value="-1.0" spread="2.8"/>
                    <measurement group_id="O4" value="-0.3" spread="6.7"/>
                    <measurement group_id="O5" value="-3.5" spread="5.0"/>
                    <measurement group_id="O6" value="1.8" spread="7.3"/>
                    <measurement group_id="O7" value="3.0" spread="8.6"/>
                    <measurement group_id="O8" value="39.0" spread="19.0"/>
                    <measurement group_id="O9" value="12.5" spread="29.0"/>
                    <measurement group_id="O10" value="16.0" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 2h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="12.8"/>
                    <measurement group_id="O2" value="-2.8" spread="9.3"/>
                    <measurement group_id="O3" value="-4.0" spread="18.2"/>
                    <measurement group_id="O4" value="-6.5" spread="7.9"/>
                    <measurement group_id="O5" value="-10.8" spread="9.6"/>
                    <measurement group_id="O6" value="3.0" spread="8.4"/>
                    <measurement group_id="O7" value="9.8" spread="8.3"/>
                    <measurement group_id="O8" value="41.3" spread="21.7"/>
                    <measurement group_id="O9" value="4.5" spread="25.3"/>
                    <measurement group_id="O10" value="10.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 4h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="15.2"/>
                    <measurement group_id="O2" value="-1.5" spread="17.1"/>
                    <measurement group_id="O3" value="-7.3" spread="3.3"/>
                    <measurement group_id="O4" value="-8.3" spread="11.9"/>
                    <measurement group_id="O5" value="-1.5" spread="7.0"/>
                    <measurement group_id="O6" value="6.0" spread="17.8"/>
                    <measurement group_id="O7" value="6.5" spread="6.2"/>
                    <measurement group_id="O8" value="38.5" spread="10.7"/>
                    <measurement group_id="O9" value="9.0" spread="28.3"/>
                    <measurement group_id="O10" value="1.8" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 6h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="4.8"/>
                    <measurement group_id="O2" value="3.7" spread="8.4"/>
                    <measurement group_id="O3" value="11.5" spread="5.8"/>
                    <measurement group_id="O4" value="4.0" spread="13.1"/>
                    <measurement group_id="O5" value="0.0" spread="14.9"/>
                    <measurement group_id="O6" value="14.0" spread="11.0"/>
                    <measurement group_id="O7" value="17.8" spread="1.0"/>
                    <measurement group_id="O8" value="41.8" spread="13.8"/>
                    <measurement group_id="O9" value="20.0" spread="15.6"/>
                    <measurement group_id="O10" value="15.5" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 8h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="12.3"/>
                    <measurement group_id="O2" value="1.2" spread="9.3"/>
                    <measurement group_id="O3" value="-4.8" spread="7.8"/>
                    <measurement group_id="O4" value="6.8" spread="14.2"/>
                    <measurement group_id="O5" value="8.5" spread="18.7"/>
                    <measurement group_id="O6" value="5.5" spread="12.1"/>
                    <measurement group_id="O7" value="8.0" spread="7.4"/>
                    <measurement group_id="O8" value="37.5" spread="19.3"/>
                    <measurement group_id="O9" value="5.0" spread="12.7"/>
                    <measurement group_id="O10" value="5.0" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 12h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="8.3"/>
                    <measurement group_id="O2" value="3.8" spread="8.9"/>
                    <measurement group_id="O3" value="-1.0" spread="2.2"/>
                    <measurement group_id="O4" value="-2.8" spread="14.0"/>
                    <measurement group_id="O5" value="2.8" spread="13.0"/>
                    <measurement group_id="O6" value="11.5" spread="13.1"/>
                    <measurement group_id="O7" value="17.8" spread="5.2"/>
                    <measurement group_id="O8" value="36.0" spread="9.4"/>
                    <measurement group_id="O9" value="17.5" spread="2.1"/>
                    <measurement group_id="O10" value="9.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at 24h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="19.3"/>
                    <measurement group_id="O2" value="0.0" spread="8.6"/>
                    <measurement group_id="O3" value="0.0" spread="11.3"/>
                    <measurement group_id="O4" value="0.8" spread="15.1"/>
                    <measurement group_id="O5" value="3.0" spread="7.1"/>
                    <measurement group_id="O6" value="1.5" spread="6.5"/>
                    <measurement group_id="O7" value="5.3" spread="9.0"/>
                    <measurement group_id="O8" value="15.8" spread="4.9"/>
                    <measurement group_id="O9" value="-0.5" spread="21.9"/>
                    <measurement group_id="O10" value="-2.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="17.6"/>
                    <measurement group_id="O2" value="13.0" spread="15.4"/>
                    <measurement group_id="O3" value="4.8" spread="18.8"/>
                    <measurement group_id="O4" value="10.8" spread="15.9"/>
                    <measurement group_id="O5" value="8.3" spread="19.8"/>
                    <measurement group_id="O6" value="13.3" spread="12.7"/>
                    <measurement group_id="O7" value="-3.5" spread="6.5"/>
                    <measurement group_id="O8" value="9.0" spread="14.4"/>
                    <measurement group_id="O9" value="9.0" spread="28.3"/>
                    <measurement group_id="O10" value="9.8" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (T1/2) of KH176 Over 24 Hours: SAD</title>
        <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T1/2) of KH176 Over 24 Hours: SAD</title>
          <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="10.3" spread="14.6"/>
                    <measurement group_id="O3" value="9.10" spread="15.2"/>
                    <measurement group_id="O4" value="9.64" spread="4.29"/>
                    <measurement group_id="O5" value="9.80" spread="19.1"/>
                    <measurement group_id="O6" value="11.5" spread="4.73"/>
                    <measurement group_id="O7" value="9.09" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (T1/2) of KH183: SAD</title>
        <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T1/2) of KH183: SAD</title>
          <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="5.86"/>
                    <measurement group_id="O2" value="17.8" spread="19.0"/>
                    <measurement group_id="O3" value="15.4" spread="8.44"/>
                    <measurement group_id="O4" value="14.3" spread="18.9"/>
                    <measurement group_id="O5" value="17.2" spread="18.5"/>
                    <measurement group_id="O6" value="18.9" spread="18.7"/>
                    <measurement group_id="O7" value="14.9" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of KH176: SAD Group</title>
        <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of KH176: SAD Group</title>
          <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="21.3"/>
                    <measurement group_id="O2" value="56.2" spread="21.0"/>
                    <measurement group_id="O3" value="167" spread="27.2"/>
                    <measurement group_id="O4" value="766" spread="53.9"/>
                    <measurement group_id="O5" value="2170" spread="27.9"/>
                    <measurement group_id="O6" value="5990" spread="20.9"/>
                    <measurement group_id="O7" value="165" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of KH183 Over 24 Hours: SAD</title>
        <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of KH183 Over 24 Hours: SAD</title>
          <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="49.5"/>
                    <measurement group_id="O2" value="49.4" spread="9.00"/>
                    <measurement group_id="O3" value="168" spread="29.6"/>
                    <measurement group_id="O4" value="497" spread="17.6"/>
                    <measurement group_id="O5" value="1100" spread="9.58"/>
                    <measurement group_id="O6" value="1780" spread="26.3"/>
                    <measurement group_id="O7" value="117" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of KH183 (Active Metabolite of KH176): MAD Group</title>
        <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Cmax was obtained directly from the concentration-time data.</description>
        <time_frame>Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Cmax Dose 100mg</title>
            <description>Maximum concentration - 100mg</description>
          </group>
          <group group_id="O2">
            <title>Cmax - Dose 200mg</title>
            <description>Maximum concentration - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>Cmax - Dose 400mg</title>
            <description>Maximum concentration - 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of KH183 (Active Metabolite of KH176): MAD Group</title>
          <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Cmax was obtained directly from the concentration-time data.</description>
          <population>Per protocol set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" spread="20.9"/>
                    <measurement group_id="O2" value="251" spread="18.0"/>
                    <measurement group_id="O3" value="550" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" spread="37.5"/>
                    <measurement group_id="O2" value="250" spread="10.6"/>
                    <measurement group_id="O3" value="450" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of KH176: MAD</title>
        <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
        <time_frame>pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Cmax Dose 100mg</title>
            <description>Maximum concentration - 100mg</description>
          </group>
          <group group_id="O2">
            <title>Cmax - Dose 200mg</title>
            <description>Maximum concentration - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>Cmax - Dose 400mg</title>
            <description>Maximum concentration - 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of KH176: MAD</title>
          <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184" spread="57.0"/>
                    <measurement group_id="O2" value="313" spread="20.0"/>
                    <measurement group_id="O3" value="1330" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353" spread="19.1"/>
                    <measurement group_id="O2" value="748" spread="29.3"/>
                    <measurement group_id="O3" value="2100" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration (Tmax) of KH176 Over 24 Hours: SAD</title>
        <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of KH176 Over 24 Hours: SAD</title>
          <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="55.5"/>
                    <measurement group_id="O2" value="1.03" spread="55.5"/>
                    <measurement group_id="O3" value="0.931" spread="83.4"/>
                    <measurement group_id="O4" value="1.10" spread="85.6"/>
                    <measurement group_id="O5" value="1.36" spread="20.5"/>
                    <measurement group_id="O6" value="0.931" spread="102"/>
                    <measurement group_id="O7" value="2.45" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Peak Plasma Concentration (Tmax) of KH183: SAD</title>
        <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Peak Plasma Concentration (Tmax) of KH183: SAD</title>
          <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="34.8"/>
                    <measurement group_id="O2" value="1.46" spread="29.1"/>
                    <measurement group_id="O3" value="1.32" spread="34.8"/>
                    <measurement group_id="O4" value="1.31" spread="34.7"/>
                    <measurement group_id="O5" value="1.61" spread="14.5"/>
                    <measurement group_id="O6" value="1.57" spread="33.7"/>
                    <measurement group_id="O7" value="2.45" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration (Tmax) of KH176 at Day 1, Day 7: MAD Group</title>
        <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
        <time_frame>pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Tmax Dose 100mg</title>
            <description>Time to Maximum concentration - 100mg</description>
          </group>
          <group group_id="O2">
            <title>Tmax - Dose 200mg</title>
            <description>Time to Maximum concentration - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>Tmax - Dose 400mg</title>
            <description>Time to Maximum concentration - 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of KH176 at Day 1, Day 7: MAD Group</title>
          <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="173"/>
                    <measurement group_id="O2" value="1.73" spread="16.7"/>
                    <measurement group_id="O3" value="0.866" spread="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.931" spread="48.1"/>
                    <measurement group_id="O2" value="1.86" spread="14.5"/>
                    <measurement group_id="O3" value="1.36" spread="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration (Tmax) of KH183 (Active Metabolite of KH176): MAD Group</title>
        <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. tmax was obtained directly from the concentration-time data.</description>
        <time_frame>Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Tmax Dose 100mg</title>
            <description>Time to Maximum concentration - 100mg</description>
          </group>
          <group group_id="O2">
            <title>Tmax - Dose 200mg</title>
            <description>Time to Maximum concentration - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>Tmax - Dose 400mg</title>
            <description>Time to Maximum concentration - 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of KH183 (Active Metabolite of KH176): MAD Group</title>
          <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. tmax was obtained directly from the concentration-time data.</description>
          <population>Per protocol set</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="116"/>
                    <measurement group_id="O2" value="1.57" spread="33.7"/>
                    <measurement group_id="O3" value="1.22" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="36.6"/>
                    <measurement group_id="O2" value="1.46" spread="29.1"/>
                    <measurement group_id="O3" value="1.61" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Factor (Racc) of KH176 Over 7 Days: MAD Group</title>
        <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. Racc was calculated as follows: AUCtau day 7/ AUCtau day 1.</description>
        <time_frame>Pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Racc Dose 100mg</title>
            <description>Accumulation factor - 100mg</description>
          </group>
          <group group_id="O2">
            <title>Racc- Dose 200mg</title>
            <description>Accumulation factor - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>Racc - Dose 400mg</title>
            <description>Accumulation factor - 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Factor (Racc) of KH176 Over 7 Days: MAD Group</title>
          <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. Racc was calculated as follows: AUCtau day 7/ AUCtau day 1.</description>
          <population>Per protocol set</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="31.2"/>
                    <measurement group_id="O2" value="2.65" spread="2.5"/>
                    <measurement group_id="O3" value="2.17" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Factor (Racc) of KH183 (Active Metabolite of KH176): MAD Group</title>
        <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Accumulation factor was calculated as follows: AUCtau day 7/ AUCtau day 1.</description>
        <time_frame>Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
        <population>Per protocol set. The placebo subjects were excluded from the PK analysis per-protocol set.</population>
        <group_list>
          <group group_id="O1">
            <title>Racc Dose 100mg</title>
            <description>Accumulation factor - 100mg</description>
          </group>
          <group group_id="O2">
            <title>Racc- Dose 200mg</title>
            <description>Accumulation factor - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>Racc - Dose 400mg</title>
            <description>Accumulation factor - 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Factor (Racc) of KH183 (Active Metabolite of KH176): MAD Group</title>
          <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Accumulation factor was calculated as follows: AUCtau day 7/ AUCtau day 1.</description>
          <population>Per protocol set. The placebo subjects were excluded from the PK analysis per-protocol set.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="46.7"/>
                    <measurement group_id="O2" value="1.32" spread="13.1"/>
                    <measurement group_id="O3" value="1.19" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH183: SAD Group</title>
        <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH183: SAD Group</title>
          <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" spread="26.7"/>
                    <measurement group_id="O2" value="547" spread="12.4"/>
                    <measurement group_id="O3" value="1810" spread="37.4"/>
                    <measurement group_id="O4" value="4830" spread="11.8"/>
                    <measurement group_id="O5" value="11700" spread="20.2"/>
                    <measurement group_id="O6" value="23900" spread="22.2"/>
                    <measurement group_id="O7" value="1590" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH176: SAD Group</title>
        <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH176: SAD Group</title>
          <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="14.8"/>
                    <measurement group_id="O2" value="389" spread="8.16"/>
                    <measurement group_id="O3" value="1310" spread="16.7"/>
                    <measurement group_id="O4" value="6320" spread="20.2"/>
                    <measurement group_id="O5" value="21000" spread="27.5"/>
                    <measurement group_id="O6" value="61200" spread="9.07"/>
                    <measurement group_id="O7" value="1650" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve (AUCtau) of KH176: MAD Group:</title>
        <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
        <time_frame>Pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>AUCtau Dose 100mg</title>
            <description>Area under the plasma concentration-time curve during a dose interval- 100mg</description>
          </group>
          <group group_id="O2">
            <title>AUCtau - Dose 200mg</title>
            <description>Area under the plasma concentration-time curve during a dose interval - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>AUCtau - Dose 400mg</title>
            <description>Area under the plasma concentration-time curve during a dose interval - 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve (AUCtau) of KH176: MAD Group:</title>
          <description>Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1090" spread="49.3"/>
                    <measurement group_id="O2" value="2250" spread="26.1"/>
                    <measurement group_id="O3" value="6890" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2760" spread="22.6"/>
                    <measurement group_id="O2" value="5960" spread="26.8"/>
                    <measurement group_id="O3" value="14900" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve During a Dose Interval (AUCtau) of KH183 (Active Metabolite of KH176): MAD Group</title>
        <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
        <time_frame>Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
        <population>Per protocol set. The placebo subjects were excluded from the PharmaocoKinetics (PK) analysis per-protocol set.</population>
        <group_list>
          <group group_id="O1">
            <title>AUCtau Dose 100mg</title>
            <description>Area under the plasma concentration-time curve during a dose interval- 100mg</description>
          </group>
          <group group_id="O2">
            <title>AUCtau - Dose 200mg</title>
            <description>Area under the plasma concentration-time curve during a dose interval - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>AUCtau - Dose 400mg</title>
            <description>Area under the plasma concentration-time curve during a dose interval - 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve During a Dose Interval (AUCtau) of KH183 (Active Metabolite of KH176): MAD Group</title>
          <description>Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
          <population>Per protocol set. The placebo subjects were excluded from the PharmaocoKinetics (PK) analysis per-protocol set.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="702" spread="29.2"/>
                    <measurement group_id="O2" value="1680" spread="21.0"/>
                    <measurement group_id="O3" value="3600" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1310" spread="29.5"/>
                    <measurement group_id="O2" value="2220" spread="12.7"/>
                    <measurement group_id="O3" value="4270" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH183: SAD</title>
        <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH183: SAD</title>
          <description>Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234" spread="26.7"/>
                    <measurement group_id="O2" value="881" spread="19.6"/>
                    <measurement group_id="O3" value="2690" spread="38.4"/>
                    <measurement group_id="O4" value="6690" spread="11.0"/>
                    <measurement group_id="O5" value="18700" spread="26.7"/>
                    <measurement group_id="O6" value="41300" spread="10.5"/>
                    <measurement group_id="O7" value="2410" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH176: SAD</title>
        <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
          <group group_id="O7">
            <title>Group I 100mg + Food</title>
            <description>100mg KH176 + high calorie/high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH176: SAD</title>
          <description>Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="474" spread="8.39"/>
                    <measurement group_id="O3" value="1540" spread="13.1"/>
                    <measurement group_id="O4" value="7500" spread="19.1"/>
                    <measurement group_id="O5" value="25800" spread="33.9"/>
                    <measurement group_id="O6" value="79100" spread="8.82"/>
                    <measurement group_id="O7" value="1970" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>KH176: Percentage of Administered Dose Excreted in Urine: SAD</title>
        <description>Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
        </group_list>
        <measure>
          <title>KH176: Percentage of Administered Dose Excreted in Urine: SAD</title>
          <description>Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>percentage of dose excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.71" spread="37.4"/>
                    <measurement group_id="O2" value="10.5" spread="45.6"/>
                    <measurement group_id="O3" value="10.4" spread="29.5"/>
                    <measurement group_id="O4" value="9.53" spread="65.2"/>
                    <measurement group_id="O5" value="10.9" spread="41.6"/>
                    <measurement group_id="O6" value="12.4" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>KH183: Percentage of Administered Dose Excreted in Urine: SAD</title>
        <description>Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
        </group_list>
        <measure>
          <title>KH183: Percentage of Administered Dose Excreted in Urine: SAD</title>
          <description>Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>percentage of dose excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" spread="53.0"/>
                    <measurement group_id="O2" value="6.42" spread="14.5"/>
                    <measurement group_id="O3" value="5.18" spread="28.8"/>
                    <measurement group_id="O4" value="3.81" spread="82.9"/>
                    <measurement group_id="O5" value="3.86" spread="31.0"/>
                    <measurement group_id="O6" value="3.33" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>KH176 + KH183: Percentage of Administered Dose Excreted in Urine: SAD</title>
        <description>Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>SAD Group I 10mg</title>
            <description>10mg KH176 - single dose</description>
          </group>
          <group group_id="O2">
            <title>SAD Group II 30mg</title>
            <description>30mg KH176 - single dose</description>
          </group>
          <group group_id="O3">
            <title>SAD Group I 100mg</title>
            <description>100mg KH176 - single dose</description>
          </group>
          <group group_id="O4">
            <title>SAD Group II 300mg</title>
            <description>300mg KH176 - single dose</description>
          </group>
          <group group_id="O5">
            <title>SAD Group I 800mg</title>
            <description>800mg KH176 - single dose</description>
          </group>
          <group group_id="O6">
            <title>SAD Group II 2000mg</title>
            <description>2000mg KH176 - single dose</description>
          </group>
        </group_list>
        <measure>
          <title>KH176 + KH183: Percentage of Administered Dose Excreted in Urine: SAD</title>
          <description>Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.</description>
          <population>Per protocol set</population>
          <units>percentage of dose excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="40.0"/>
                    <measurement group_id="O2" value="17.2" spread="28.6"/>
                    <measurement group_id="O3" value="15.8" spread="24.5"/>
                    <measurement group_id="O4" value="13.4" spread="69.9"/>
                    <measurement group_id="O5" value="14.8" spread="38.4"/>
                    <measurement group_id="O6" value="15.9" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>KH176: Percentage of Administered Dose Excreted in Urine: MAD</title>
        <description>Urine concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
        <time_frame>Day 7 post dose</time_frame>
        <population>Per protocol set. The placebo subjects were excluded from the Pharmacokinetics (PK) analysis per-protocol set.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group Dose 100mg</title>
            <description>100mg KH176 - Multiple dose: Percentage of administered dose excreted</description>
          </group>
          <group group_id="O2">
            <title>MAD Group - Dose 200mg</title>
            <description>200mg KH176 - Multiple dose: Percentage of administered dose excreted</description>
          </group>
          <group group_id="O3">
            <title>MAD Group - Dose 400mg</title>
            <description>400mg KH176 - Percentage of administered dose excreted</description>
          </group>
        </group_list>
        <measure>
          <title>KH176: Percentage of Administered Dose Excreted in Urine: MAD</title>
          <description>Urine concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
          <population>Per protocol set. The placebo subjects were excluded from the Pharmacokinetics (PK) analysis per-protocol set.</population>
          <units>percentage of dose excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="77.8"/>
                    <measurement group_id="O2" value="13.4" spread="36.4"/>
                    <measurement group_id="O3" value="14.0" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>KH183: Percentage of Administered Dose Excreted in Urine: MAD</title>
        <description>Urine concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
        <time_frame>Post dose Day 7</time_frame>
        <population>Per protocol set. The placebo subjects were excluded from the Pharmacokinetics (PK) analysis per-protocol set.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group Dose 100mg</title>
            <description>100mg KH176 - Multiple dose: Percentage of administered dose excreted</description>
          </group>
          <group group_id="O2">
            <title>MAD Group - Dose 200mg</title>
            <description>200mg KH176 - Multiple dose: Percentage of administered dose excreted</description>
          </group>
          <group group_id="O3">
            <title>MAD Group - Dose 400mg</title>
            <description>400mg KH176 - Percentage of administered dose excreted</description>
          </group>
        </group_list>
        <measure>
          <title>KH183: Percentage of Administered Dose Excreted in Urine: MAD</title>
          <description>Urine concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
          <population>Per protocol set. The placebo subjects were excluded from the Pharmacokinetics (PK) analysis per-protocol set.</population>
          <units>percentage of dose excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" spread="120.2"/>
                    <measurement group_id="O2" value="3.79" spread="39.2"/>
                    <measurement group_id="O3" value="4.85" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>KH173 + KH183: Percentage of Administered Dose Excreted in Urine: MAD</title>
        <description>Urine concentrations of KH176 and KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
        <time_frame>Day 7 Post dose</time_frame>
        <population>Per protocol set. The placebo subjects were excluded from the Pharmacokinetics (PK) analysis per-protocol set.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD Group Dose 100mg</title>
            <description>100mg KH176 - Multiple dose: Percentage of administered dose excreted</description>
          </group>
          <group group_id="O2">
            <title>MAD Group - Dose 200mg</title>
            <description>200mg KH176 - Multiple dose: Percentage of administered dose excreted</description>
          </group>
          <group group_id="O3">
            <title>MAD Group - Dose 400mg</title>
            <description>400mg KH176 - Percentage of administered dose excreted</description>
          </group>
        </group_list>
        <measure>
          <title>KH173 + KH183: Percentage of Administered Dose Excreted in Urine: MAD</title>
          <description>Urine concentrations of KH176 and KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.</description>
          <population>Per protocol set. The placebo subjects were excluded from the Pharmacokinetics (PK) analysis per-protocol set.</population>
          <units>percentage of dose excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="79.3"/>
                    <measurement group_id="O2" value="17.4" spread="33.3"/>
                    <measurement group_id="O3" value="19.0" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group I Placebo</title>
          <description>Placebo - single dose</description>
        </group>
        <group group_id="E2">
          <title>Group II Placebo</title>
          <description>Placebo - single dose</description>
        </group>
        <group group_id="E3">
          <title>SAD Group I 10mg</title>
          <description>10mg KH176 - single dose</description>
        </group>
        <group group_id="E4">
          <title>SAD Group II 30mg</title>
          <description>30mg KH176 - single dose</description>
        </group>
        <group group_id="E5">
          <title>SAD Group I 100mg</title>
          <description>100mg KH176 - single dose</description>
        </group>
        <group group_id="E6">
          <title>SAD Group II 300mg</title>
          <description>300mg KH176 - single dose</description>
        </group>
        <group group_id="E7">
          <title>SAD Group I 800mg</title>
          <description>800mg KH176 - single dose</description>
        </group>
        <group group_id="E8">
          <title>SAD Group II 2000mg</title>
          <description>2000mg KH176 - single dose</description>
        </group>
        <group group_id="E9">
          <title>Group I Placebo + Food</title>
          <description>Placebo + high calorie/high fat breakfast</description>
        </group>
        <group group_id="E10">
          <title>Group I 100mg + Food</title>
          <description>100mg KH176 + high calorie/high fat breakfast</description>
        </group>
        <group group_id="E11">
          <title>MAD Group III 200mg</title>
          <description>100mg BID/Day (over 7 days)</description>
        </group>
        <group group_id="E12">
          <title>MAD Group IV 400mg</title>
          <description>200mg BID/Day (over 7 days)</description>
        </group>
        <group group_id="E13">
          <title>MAD Group V 800mg</title>
          <description>400mg BID/Day (over 7 days)</description>
        </group>
        <group group_id="E14">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1.</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Brundle branch block right</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatinine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="5" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="5" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bradyphrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Depersonalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edwin Spaans, PharmD.</name_or_title>
      <organization>Khondrion B.V.</organization>
      <phone>+31654997700</phone>
      <email>spaans@khondrion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

